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AGATING MECHANISMS OF THE CANONICAL TRP CHANNEL ISOFORM TRPC4

Dhananjay Thakur, M.Sc., M.S.

Advisory Professor: Michael X. Zhu, Ph.D.

Non-selective cation channels formed by Transient Receptor Potential Canonical (TRPC)
proteins play important roles in regulatory and pathophysiological processes. These channels are
known to be activated downstream from phospholipase C (PLC) signaling. However, the
mechanism by which the PLC pathway activates TRPC4/C5 remains unclear. Uniquely, TRPC4
is maximally activated only when two separate G protein pathways, Gq/11 and Gi/o, are costimulated, making it a coincidence detector of Gq/11- and Gi/o -coupled receptor activation. Using
HEK293 cells co-expressing mouse TRPC4β and selected G protein-coupled receptors, I observed
that coincident stimulation of Gi/o proteins and PLCδ1 (and not Gq/11-PLCβ) is necessary and
sufficient for TRPC4 activation. In cells co-expressing TRPC4 and Gi/o -coupled µ opioid
receptor, µ agonist DAMGO elicited currents in a biphasic manner, with an initial slow phase
preceding a second, rapidly developing phase. While the currents were dependent on intracellular
Ca2+ and phosphatidylinositol 4,5-bisphosphate (PIP2), both Ca2+ and PIP2 also exhibited
inhibitory effects. Depleting PIP2 abolished the biphasic kinetics and facilitated channel activation
by weak Gi/o stimulation. TRPC4 activation was inhibited by knocking down PLCδ1 and almost
entirely eliminated by a dominant-negative PLCδ1 mutant or a constitutively active RhoA mutant.
These results demonstrate an integrative mechanism of TRPC4 for detection of coincident Gi/o,
vii

Ca2+, and PLC signaling, wherein TRPC4 and PLCδ1 are functionally coupled. This mechanism
is not shared with the closely related TRPC5, implicating unique roles of TRPC4 in signal
integration. Intracellular acidification further facilitated channel activation in a bimodal manner,
with moderate acidification accelerating the Gi/o-TRPC4 response, while strong acidification was
inhibitory. This regulation by H+ is functionally and mechanistically distinct from that by Ca2+,
which involves not only Ca2+-dependent PLCδ1 activation but also a direct modulation by Ca2+calmodulin. Thus, our findings indicate that TRPC4 is maximally activated when (A) Gi/o and
PLCδ1 are stimulated and (B) intracellular concentrations of PIP2, Ca2+ and H+ fall within specific
ranges. These findings indicate that TRPC4 serves as a unique coincidence sensor of intracellular
environmental changes that accompany not only Gi/o stimulation and PLC signaling but also,
likely, other pathophysiological conditions, such as metabolic changes and hypoxic stress.
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Chapter 1
Introduction

Transient receptor potential channels (TRPs) function as sensors and transducers of a wide
variety of environmental and endogenous signals. Within the TRP channel superfamily, members
of the Canonical class of TRPs (TRPC) are activated downstream of G-Protein Coupled Receptors
(GPCRs) and receptor tyrosine kinases (RTK). GPCRs and RTK receptors transduce biochemical
signals (in the form of neurotransmitters, hormones, growth factors and their exogenous analogs),
into multiple regulatory or pathophysiological processes. A primary downstream event in
receptor-TRPC pathways is the change in [Ca2+]i (intracellular Ca2+ concentrations). Temporal
and spatial control of [Ca2+]i regulates a variety of phenomena including: cell excitability,
contraction, secretion, migration, adhesion, gene expression and cell death.
There are several overlaps in the expression profiles of the various TRPC isoforms and
several direct and functional interactions within the TRPC sub-family. Although their effects on
a variety of cellular events have been observed, their precise contribution(s) are only partly
understood, mostly because very little is known about the activation and regulation mechanisms
of the various isoforms within this sub-family. Although the Gq/11 phospholipase C-β (PLCβ) and
phospholipase C-γ (PLCγ) pathways have been identified as the primary upstream events for the
activation of most TRPCs, TRPC4 and TRPC5 are uniquely sensitive to Gi/o coupled receptor
activation (Otsuguro, Tang et al. 2008, Jeon, Hong et al. 2012). In this case, while the Gq/11-PLC
pathway is well characterized, the physiological significance and molecular mechanisms of Gi/o
mediated TRPC4 and TRPC5 activation are unknown. TRPC5 can be activated maximally
1

downstream of Gq/11 alone. However, Gi/o activation is obligatory to obtain maximal TRPC4
currents. In this study, while there appeared to be a PLC component necessary for TRPC4
activation, it was distinct to the Gq/11-PLC pathway, suggesting a novel mechanism unique to
TRPC4. Elucidation of this pathway would shed light on the physiological significance of TRPC4
function with respect to Gi/o, Gq/11 and RTK mediated signaling. Therefore, the major aim of this
dissertation was to identify the mechanism(s) underlying the activation and regulation of the
channels formed by the TRPC4 isoform.

1.1 Historical background
Early research (1910 ~ 1960) on fruit flies (Drosophila melanogaster) focused on genetic
manipulations to study heredity. Subsequently, the accumulation of a vast body of knowledge and
expertise in Drosophila genetics prompted an interest in using fruit flies to examine physiological
processes. In search for mutations that would result in neurological impairment in Drosophila,
Cosens and Manning discovered a mutation that resulted in a retinal defect making flies behave
as if they were blind (Cosens and Manning 1969). It was then noted that this mutation resulted in
a fast decay of an electroretinogram (ERG) signal during strong light stimulation - compared to
the sustained plateau ERG seen in the wild type fly. Therefore, the name Transient Receptor
Potential (TRP) was coined (Minke, Wu et al. 1975).
However, it was not until 15 years later that Montell and Rubin cloned the gene
responsible for this mutation and predicted a protein structure that could constitute a channelforming transmembrane protein (Montell and Rubin 1989). Two years following this discovery,
Hardie and Minke were able to record light-induced currents from both wild type and trp mutant
flies and demonstrated that the mutant suffered from the loss of a sustained Ca2+ dependent current
2

downstream of rhodopsin and inositol 1,4,5-trisphosphate (IP3) receptor activation (Hardie and
Minke 1991). Subsequently, two independent groups cloned the first mammalian TRP homolog,
TRP1 (or TRPC1) (Wes, Chevesich et al. 1995, Zhu, Chu et al. 1995). Thereafter, six more
mammalian homologs based on sequence homology were cloned in full-length (Philipp, Cavalié
et al. 1996, Zhu, Jiang et al. 1996, Okada, Shimizu et al. 1998, Philipp, Hambrecht et al. 1998,
Okada, Inoue et al. 1999).
Outside of the canonical class, but showing significant sequence similarities, a wide
variety of channel-forming proteins were discovered, and later, uniformly designated as TRP
superfamily members (Montell, Birnbaumer et al. 2002). Interest in TRP proteins developed
rapidly and one of the most widely noted discoveries was that of the high temperature sensor
vanilloid receptor 1 (VR1) or transient receptor potential vanilloid (TRPV1) which was also
activated by capsaicin, the active ingredient of chili peppers (Caterina, Schumacher et al. 1997).
Three other genes, closely homologous to TRPV1, designated TRPV2-4, were subsequently
cloned and showed different warm-temperature thresholds. At the opposite end of the temperature
spectrum, two independent groups discovered a cool temperature-activated TRP channel,
transient receptor potential melastatin 8 (TRPM8) (McKemy, Neuhausser et al. 2002, Peier,
Moqrich et al. 2002). TRPM8 is activated at temperatures approximately below 26 °C. Then the
transient receptor potential ANKTM1 (TRPA1) channel was discovered and shown to be highly
sensitive to cold temperatures (Story, Peier et al. 2003) and the compound allyl isothiocyanate
(Bandell, Story et al. 2004, Jordt, Bautista et al. 2004). TRPA1 is activated at a lower temperature
threshold (~14 °C) than TRPM8 (Sawada, Hosokawa et al. 2007, Karashima, Talavera et al.
2009). These characteristics impart distinct roles for TRPM8 and TRPA1 as cool and cold sensors,
respectively. In addition, there is a difference in modalities of thermosensation between species
3

even though there is strong conservation of sequence for these isoforms. For instance, the
Drosophila and snake TRPA1 channels are warm temperature sensors (Rosenzweig, Brennan et
al. 2005, Hamada, Rosenzweig et al. 2008, Gracheva, Ingolia et al. 2010).
In general, based on sequence alignment and function, the mammalian TRP superfamily
was divided into six sub-families: canonical TRPs (TRPC) are those that show highest homology
to the original Drosophila TRP protein; melastatin TRPs (TRPM), named after the founding
member Melastatin (TRPM1); vanilloid TRPs (TRPV) named after the founding member
vanilloid receptor 1 (VR1 or TRPV1); Ankyrin TRP (TRPA1) representing the single mammalian
ANK-TRP; polycystin TRPs (TRPP) named after polycystic kidney disease gene PKD2 and
mucolipin TRPs (TRPML) which are homologs of the gene responsible for mucolipidosis type
IV (Montell, Birnbaumer et al. 2002). Some TRPs, such as the transient receptor potential NOMP
(TRPN) are only found in invertebrates. So far, by species, the number of TRP channel genes
identified are: 28 in rodents, 27 in human, 17 in C. elegans, and 13 in Drosophila (Montell 2011).
The evolutionary relationships of mammalian TRPC proteins along with the Drosophila TRP are
shown in figure 1.
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Figure 1. Evolutionary relationship of TRPC homologs
Phylogenetic tree of Drosophila TRP (red) and mammalian (mouse) TRPCs (blue) constructed
using ClustalW-Phylogeny. Known mechanisms upstream of TRP and TRPC activation are
shown to the right in grey
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TRPC channel subunits can assemble into homotetramers as well as heterotetramers (Fig
2). It has been suggested that the sequence similarities between TRPC subclasses (between TRPCs
1, 4 and 5 vs. TRPCs 3, 6 and 7) might underlie their preference for heteromerization (Schaefer
2005). However, as yet, a rule that governs heteromerizing combinations has not been established.
Empirically determined heteromerizing partners that have been identified so far are: TRPC1 with
TRPC3, 4, 5, 7; TRPC3 with TRPC4; TRPC3 with TRPC6, 7; TRPC4 with TRPC5; TRPC6 with
TRPC3, 7; TRPC7 with TRPC3,6 (Poteser, Graziani et al. 2006, Ambudkar and Ong 2007).
The isoforms TRPC1, 3, 4, 5, 6, 7 are ubiquitous in human tissues with varying
heteromerizing-combinations and expression levels. As a consequence of this, they show diverse
functions throughout the body (Abramowitz and Birnbaumer 2009). The exception - TRPC2, is a
pseudogene in humans (Wes, Chevesich et al. 1995), apes and old world monkeys (Zhang and
Webb 2003). However, in mice and rats it plays a principal role in pheromone sensing (Freichel,
Vennekens et al. 2004).
With the exception of TRPC4 and TRPC5, all mammalian isoforms are maximally
activated downstream of the Gq-PLCβ or PLCγ pathways (Fig. 1). TRPC5 can be maximally
activated downstream of Gi/o protein activation in addition to Gq-PLCβ or PLCγ activation.
However, maximal activation of TRPC4 is highly selective to Gi/o activation (Otsuguro, Tang et
al. 2008, Jeon, Hong et al. 2012).

6

1.2 Basic structure of TRPCs
Each TRPC subunit consists of six transmembrane segments (S1-S6) with both N and C
termini located in the cytoplasm (Fig. 2a). The P-loop is found between the segments S5 and S6,
similar to the P-loop of voltage-gated potassium (Kv) channels and determines ionic selectivity.
Composite channels are formed when four subunits assemble to form a tetramer (Fig. 2b). Similar
to Kv channels, two sets of interactions are involved for assembly – one between N termini and
the other between C termini and N termini of different subunits (Lepage, Lussier et al. 2006).
TRPC3, 6, 7 share ~75% homology and TRPC4, 5 share 65% homology. All TRPC isoforms
contain the conserved amino acid sequence EWKFAR (the TRP domain), which is also common,
with less conservation, to the TRP superfamily at the C-termini. They have upto 4 ankyrin-like
repeats at their N termini which are thought to be important for heteromerization and lipid and
protein interactions (Gaudet 2008). TRPCs have a competitive Ca2+/CaM (calmodulin) and IP3
receptor (IP3R) binding (CIRB) site at their C termini (Zhang, Tang et al 2001). Along with CaM
and IP3R, all TRPC isoforms participate in a diverse range of protein-protein interactions with
STIM, Orai, SESTD1, Homer, Junctate, sodium hydrogen exchanger regulatory factor (NHERF)
and several other proteins (Kiselyov, Kim et al. 2005, Ong and Ambudkar 2011). As this work
primarily deals with TRPC4 (and to a lesser extent TRPC5), the domains of TRPC4 and TRPC5
subunits are labeled in detail in Fig. 3 below.
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Figure 2. Topology of TRPC channels
a. Rendering of a single TRPC subunit (not to scale) consisting of cytoplasmic N and C termini
and 6 transmembrane segments. Various protein and lipid interacting domains on N and C termini
are indicated. b. A TRPC-containing channel is formed by assembly of four subunits into
homomeric or heteromeric complexes with each subunit contributing a pore loop (P-loop) that
imparts the selectivity filter to the channel complex.
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Figure 3. Important domains in TRPC4 and TRPC5
An 84 amino acid region encoding a phosphatidylinositol (4,5)-bisphosphate (PIP2) and CaM
binding site is truncated in TRPC4β, as compared to the TRPC4 isoform. TRPC5 is closely
homologous, yet shares only a 65% sequence similarity with TRPC4α with maximum diversity
seen in the C termini of the two proteins with 44% identity measured using NCBI Protein BLAST.
Ank: ankyrin-like domain, SESTD1: SEC14 and spectrin domains 1
1.3 Endogenous regulatory pathways
Stimulation of Gq/11 coupled receptors and RTKs activates downstream effectors
phospholipases PLCβ and PLCγ, respectively, which hydrolyze the membrane phospholipid PIP2.
The products of phosphatidylinositol (4,5)-bisphosphate (PIP2) hydrolysis are diacylglycerols
(DAG) and IP3. Though the precise mechanism is not fully understood, DAG directly activates
TRPC3, 6, 7 but has no effect on the activity of TRPC4 and 5. The other product of PIP2
hydrolysis, IP3 activates IP3 receptors expressed on the membranes of intracellular Ca2+ stores
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such as the endoplasmic reticulum - releasing Ca2+ into the cytosol which can sensitize TRPC4,
5 activity and desensitize TRPC3, 6, 7.

Figure 4. Activation mechanism of TRPC channels
The Gq-PLC pathway that induces TRPC activation contains several elements downstream of PIP2
hydrolysis that differentially modulate TRPC isoforms. Several DAG species and polyunsaturated
fatty acids (PUFAs) have been shown to be essential for Drosophila TRP activation (Chyb, Raghu
et al. 1999). Protons generated during hydrolysis of PIP2 modulate the Drosophila TRP activation
(Huang, Liu et al. 2010). However, their role in the modulation of mammalian TRPCs is not well
understood.
Ca2+, Ca2+ binding proteins, IP3 receptors and phosphokinases modulate all TRPC
isoforms. As mentioned before, uniquely, Gi/o coupled receptors have been shown to have an
excitatory effect on TRPC4 and TRPC5 (Otsuguro, Tang et al. 2008, Jeon, Hong et al. 2012). In
addition to being key players in Receptor Operated Calcium Entry (ROCE) (De Petrocellis and
Di Marzo 2009), direct sensitivity to Ca2+ or to Ca2+ sensing proteins such as CaM and stromal
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interacting molecules (STIMs) also allows TRPCs to participate in Store Operated Calcium Entry
(SOCE) (Li, Sukumar et al. 2008, Blair, Kaczmarek et al. 2009, Gross, Guzman et al. 2009)
Influx of Ca2+ and GPCR activation can also lead to vesicular trafficking to the plasma
membrane. TRPCs sequestered in vesicular membranes are therefore trafficked to the plasma
membrane downstream of Ca2+ influx/GPCR activation after which they show increased basal
and/or stimulated activity. Therefore, there are several distinct modes of TRPC recruitment: by G
protein activation, PLC activation, trafficking to the plasma membrane and intracellular increase
in Ca2+.

1.4 Ionic selectivity and effects on membrane excitability
Though all TRPCs are non-selective for cations, their preference for conduction of Ca2+
over Na+, Mg2+, K+ and other cations varies individually and is not predicted by their sequence or
subclassification mentioned above. There is considerable variation in the ionic specificities
measured in different laboratories. For example, Gees et al. collected the assortment of
permeability measurements which show that: while relative permeability for Ca2+ over Na+ can
be upto 10:1 (for PCa2+/PNa+(or

Cs+):

TRPC5 >TRPC6 >TRPC7 >TRPC2 >TRPC3 >TRPC4

>TRPC1), a few studies indicate more permeability for Na+ than Ca2+ for some but not all TRPC
isoforms (Gees, Colsoul et al 2010)(Eder, Poteser et al. 2005). For all isoforms, the total cationic
influx (INa+ + ICa2+) can sufficiently depolarize the membrane to activate voltage gated calcium
channels which trigger contraction in smooth muscle cells and activation of voltage gated sodium
channels in neurons (Gross, Guzman et al. 2009, Phelan, Shwe et al. 2013). Additionally, some
TRPCs directly couple to membrane ion transporters such as the Na+-Ca2+ exchanger (NCX)
(Eder, Probst et al. 2007). NCX operation depends on the membrane potential and concentration
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gradients for Na+ and Ca2+. In the ‘forward mode’, when cytosolic Ca2+ levels rise, it transports
Ca2+ out of the cell to restore resting Ca2+ levels inside the cell and transports Na+ inwardly in
exchange of Ca2+ efflux. The Na+ influx through TRPC channels raises intracellular [Na+], which
drives the “reverse mode” of NCX. This reverses the action of the exchanger for Na+ efflux and
Ca2+ influx, amplifying the Ca2+ load in the cell (Eder, Poteser et al. 2005, Eder, Probst et al.
2007). Moreover, NCX can function in both ‘forward’ and ‘reverse’ modes in different locations
of the cell depending on local membrane ionic environments. Therefore, in combination with
TRPC activity, NCX activity adds another significant dimension in the spatiotemporal modulation
of [Ca2+]i and membrane potential. TRPCs also associate with large conductance Ca2+-activated
potassium (BK) channels which are activated by Ca2+ influx through TRPCs (Kwan, Shen et al.
2009). Activation of BK hyperpolarizes the membrane. Therefore, though the spatiotemporally
localized effect of TRPC activation is a depolarizing cationic influx, globally - TRPC activation
may cause either depolarization or hyperpolarization, depending on association with other
proteins either directly or in signal-complexes. The ionic selectivity of heteromeric TRPCs has
not been thoroughly investigated and is of particular interest in order to determine whether
natively expressed TRPCs function solely as [Ca2+]i modulators or also as key mediators of
membrane excitability.

1.5 Sensitivity to lipids and endogenous/exogenous ligands
The effects of the membrane phospholipid PIP2 on TRPCs are varied and complex. PIP2
inhibits TRPC3, 6 and 7 (Albert, Saleh et al. 2008, Itsuki, Imai et al. 2014) whereas PLC
hydrolysis of PIP2 is essential for TRPC4 and TRPC5 activation as the application of exogenous
PIP2 inhibits TRPC4 and TRPC5 activities (Otsuguro, Tang et al. 2008, Kim, Kim et al. 2008,
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Trebak, Lemonnier et al. 2009, Kim, Jeon et al. 2013). However, depletion of PIP2 using
phosphatases other than PLC inhibited TRPC5, implying that a critical initial level of PIP2 has to
be maintained at the plasma membrane for the activation of these channels (Trebak, Lemonnier
et al. 2009). Whether the PIP2 dependence of the current stems from a PIP2 dependent membrane
localization is not known. In studies conducted in human platelets, TRPC1, 4, 5 were shown to
localize in detergent resistant cholesterol rich lipid rafts and that disruption of this localization
resulted in a reduction of channel response to agonist application (Brownlow and Sage 2005).
TRPC3, 6 are found in two populations – lipid raft bound and ‘freely floating’ in the plasma
membrane unaffected by cholesterol depletion. However, these effects vary by cell type and may
depend on several other factors such as scaffolding proteins and protein-binding partners such as
caveolin-1 (Levitan, Fang et al. 2010).
Lysophospholipids such as lysophosphatidylcholine (LPC) can activate TRPCs
(Flemming, Dedman et al. 2006). Group-6 phospholipase A2 (PLA2) enzymes, which generate
LPC, are upstream of channel activation (Al-Shawaf, Tumova et al. 2011). Oxidized
phospholipids, 1-palmitoyl-2- glutaroyl-phosphatidylcholine and 1-palmitoyl-2-oxovaleroylphosphatidylcholine, activated TRPC5 in a Gi/o dependent manner (Al-Shawaf, Naylor et al.
2010). Eicosanoid compound, 20-hydroxy-eicosatetra-enoic acid (20-HETE), an important
arachidonic acid metabolite, activated mouse TRPC6 (Basora, Boulay et al. 2003). Flufenamic
acid can reversibly enhance TRPC6 currents at micromolar concentrations, whereas it inhibits
TRPC3 and TRPC7 (Jung, Strotmann et al. 2002).
Redox states, through unknown mechanisms, can stimulate homomeric TRPC3 and
heteromeric TRPC3/4 channels in native systems (Poteser, Graziani et al. 2006). Nitric oxide
activates TRPC5 by S-nitrosylation of Cys553 and Cys 558 residues approached from the
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cytoplasmic side and the formation of a disulfide bond that stabilizes the open state of the channel
(Yoshida, Inoue et al. 2006). Paradoxically, extracellular thioredoxins or dithiothreitol can break
the disulphide bridge, involving the same Cys553 residue thought to be in the extracellular loop
adjacent to the ion selectivity filter of TRPC5 and potently activate the channel, implying that
TRPC5 senses both oxidizing and reducing agents (Xu, Sukumar et al. 2008, Takahashi and Mori
2011).
The lanthanides La3+ or Gd3+ differentially modulate TRPC sub-families TRPC4, 5
(potentiation) and TRPC1, 3, 6, 7 (inhibition) and are therefore commonly used in laboratories to
distinguish between the subfamilies. TRPC1, 3, 6, 7 are inhibited by La3+ or Gd3+ in the
submicromolar to several hundred micromolar range whereas TRPC4, 5 are potentiated by these
cations in the same concentration range. Although the precise mechanism of this differential
modulation for TRPC channels is not known, for TRPC5, two glutamate residues situated close
to the mouth of pore have been suggested to be responsible for the La3+ sensitivity (Jung, Muhle
et al. 2003). These sites are also implicated in sensitivity of TRPC5 to protons, where low
extracellular pH has a similar effect as lanthanides – inhibition of TRPC6 and potentiation of
TRPC4, 5 (Semtner, Schaefer et al. 2007). Compounds containing mercury have been shown to
activate TRPC4, 5 but not other TRPC isoforms. In this case, extracellular cysteine residues have
been identified near the TRPC5 P-loop to be mercury sensors (Xu, Zeng et al. 2012). TRPC5 has
also been shown to be sensitive to anesthetics such as halothane, chloroform and propofol though
the exact mechanisms have not been identified (Bahnasi, Wright et al. 2008). Extensive
characterization of TRPC5 as a detector of exogenous ionic, redox and lipid sensitive molecules
has led to the channel being proposed as a toxicity sensor. Whether by homology TRPC4 or other
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TRPCs also share this characteristic is not known and remains an interesting avenue for
exploration.
As is the case for other TRP superfamilies, TRPCs are not gated at physiological potentials
but show voltage dependent gating when depolarized to high, positive, non-physiological
potentials. Stimulation of TRPCs using ligands left-shifts the voltage dependence to allow
activation at physiological potentials. Though voltage dependence has not been thoroughly
characterized for all TRPCs, TRPC5 has been shown to have both voltage dependent and voltage
independent states (Obukhov and Nowycky 2008). Ligands, such as La3+, promote reversible
transitions to the voltage independent state. Membrane stretch originating from flow stress or
pressure has been suggested to activate mechanically induced calcium entry into cells and TRPC1,
5, 6 have been suggested to be the channels underlying this event. While ligand independent
stretch can stimulate TRPC6 via activation of Gq (Sharif-Naeini, Folgering et al. 2010). Gq
independent TRPC6 mechanosensitivity has also been demonstrated (Spassova, Hewavitharana
et al. 2006). It has been suggested that temperature changes can also regulate TRPC activity,
though only homomeric TRPC5 has been shown to be highly sensitive to temperature changes in
the range of 37-25 oC (Zimmermann, Lennerz et al. 2011).
Dissecting TRPC-activated pathways and their physiological significance and
identification of specific targets for therapy are often complicated by the fact that they contribute
to both SOCE and ROCE in concert with STIM, homomeric TRPC1 and Orai proteins. An
additional complicating factor is that they can heteromerize to significantly alter the properties of
the assembled channels, such as in the case of TRPC1 heteromerizing with TRPC4 or TRPC5,
where the conductance of the channel is reduced by 10-fold. At the single channel levels there is
little agreement over the measured conductance, with different values for the same channel being
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reported by different groups. It has been suggested that heteromerization and different pore
structures may account for this variation and add to the diversity of TRPC modalities.
1.6 Drugs targeting TRPCs
Thermo-sensitive TRPs have attracted a majority of the early efforts in drug discovery as
they offer viable and specific targets for pain treatment (several thermo-TRP antagonists are in
clinical trials). In comparison, the screening and identification of drugs for TRPCs is in its nascent
stages. The lack of specific agonists/antagonists for TRPCs has also hindered wider exploration
of their physiological roles. Many experimentally used blockers, such as flufenamic acid and 2aminoethoxydiphenyl borate (2-APB), have to be used at concentrations that exhibit non-specific
effects and are thus unreliable for distinguishing between TRPC isoforms and for establishing the
physiological role of TRPCs. However, recent discoveries of agonists and antagonists for TRPC
isoforms, such as ML-204 which is a specific antagonist of TRPC4 and TRPC5 (Miller, Shi et al.
2011), englerin-A which has been identified as a specific TRPC4 and TRPC5 activator (Akbulut,
Gaunt et al. 2015), SAR7334 which inhibits TRPC6, TRPC3 and TRPC7 (but not TRPC4 and
TRPC5) (Maier, Follmann et al. 2015) and pyrazoles (Pyr6 and Py10) which can distinguish
between TRPC3 and Orai mediated ROCE (Schleifer, Doleschal et al. 2012), provide important
experimental- and possibly, therapeutic- tools.
While cryogenic-electron microscopy (cryo-EM) structures have been constructed for
TRPV1 (Cao, Liao et al. 2013, Liao, Cao et al. 2013) and TRPA1 (Paulsen, Armache et al. 2015),
neither X-ray crystallographic nor cryo-EM techniques have been applied to TRPC isoforms. In
conjunction with physiological and biochemical assays, drug screens and structure elucidation
would provide a more comprehensive picture of TRPC regulatory mechanisms and
pharmacology.
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1.7 Physiological functions of TRPC isoforms
1.7.1 TRPCs in the nervous system
Relatively high expression levels of TRPCs and heterogeneity of expression in the nervous
system has stimulated several research groups to focus on the function of TRPCs in different brain
regions (Strübing, Krapivinsky et al. 2001, 2003, Fowler, Sidiropoulou et al. 2007). Significant
contribution of TRPCs have been noted in neuronal development, synaptic function (Abramowitz
and Birnbaumer 2009, Bollimuntha, Selvaraj et al. 2011), and neuromodulation in mature neurons
- where TRPC channels mediate membrane depolarization downstream of GPCR and
neurotrophin receptor stimulation (Plant and Schaefer, 2005, Bollimuntha, Selvaraj et al. 2011,
Li, Xu et al. 1999, Amaral and Pozzo-Miller 2007). TRPC knock-out (KO; also denoted by ‘-/-’)
mice and rats (in which individual or groups of TRPCs encoding genes have been inactivated)
have been useful laboratory tools for examining physiological roles of TRPCs. Reminiscent of
the sustained cationic influx associated with the Drosophila TRP, mammalian TRPC-mediated
[Ca2+]i elevation and membrane depolarization are slow and long lasting compared to NMDA,
AMPA or voltage gated channel behavior. These differences in kinetics have been noted to be
potentially important for the modulation of learning and memory associated long-term
potentiation (LTP), long-term depression (LTD), and synaptic plasticity.
In the nervous system, TRPC isoforms have been observed to have diverse functions.
TRPC1 is widely expressed in different brain regions and influences the function of other TRPC
isoforms. In astrocytes isolated from the mouse visual cortex, TRPC1 contributes to [Ca2+]i
increase downstream of GPCR stimulation, leading to glutamate release (Malarkey, Ni et al.
2008). In cultured Xenopus spinal neurons, TRPC1 is necessary for the turning of growth cones
(Shim, Goh et al. 2005, Wang and Poo 2005).
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Although TRPC2 is a pseudogene in humans, apes and old-world monkeys, it has high
expression levels in other mammals. In mice, it is expressed in the vomeronasal organ, dorsal root
ganglion (DRG) and brain. However, in rats, its expression is thought to be restricted to the
vomeronasal organ (Löf, Viitanen et al. 2011). TRPC2 is essential for olfactory signal
transduction. TRPC2-/- mice showed significant effects in social and sexual behavior with reduced
aggression in both males and females and a lack of sexual discrimination during mating (Stowers,
Holy et al. 2002, Leypold, Yu et al. 2002).
Lateral septal (LS) neurons express high levels of TRPC4-containing channels along with
group I metabotropic glutamate receptors (mGluRs). TRPC4-containing channels integrate
mGluR stimulation with intracellular Ca2+ signals to generate two inter-convertible depolarization
responses – 1) a below threshold depolarization (BTD) characterized by an immediate increase in
firing rate and 2) an above-threshold-plateau-depolarization (ATPD) characterized by an initial
burst followed by a pause of firing (Tian, Thakur et al. 2013). BTD and ATPD are entirely absent
in TRPC4-/- mice. Therefore, TRPC4, downstream of metabotropic receptor activation, directly
affects excitability of LS neurons. The inter-conversion of BTD and ATPD depends on the
strength of activation of TRPC4, which in turn, might depend on the strength of the receptor and
G protein stimulation in addition to [Ca2+]i rise.
Showcasing a severe effect, stimulation of mGluRs in mouse brain slices resulted in
elicited epileptiform discharges in CA1/CA3 neurons (Wang, Bianchi et al. 2007, Phelan, Shwe
et al., 2013). The CA1 discharge is absent in either TRPC1-/- or TRPC1-/-/TRPC4-/- (double KO)
mice but is unaffected in TRPC5-/- mice (Phelan, Shwe et al., 2013). In TRPC5-/-, (but not TRPC1/-

or TRPC1-/-/TRPC4-/-) LTP in Schaffer collateral synapses (in the hippocampal CA1) is ablated,
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strongly indicating divergent and distinct roles for TRPC1/C4 and TRPC5 channels in the
hippocampus (Phelan, Shwe et al., 2013).
TRPC1/4- and 5-containing channels have also been identified as mediators in
excitotoxicity. The hippocampi and dorsolateral septa of TRPC1-/-/TRPC4-/- mice and hippocampi
of TRPC5-/- mice show reduced seizure-induced neuronal death (Phelan, Mock et al., 2012),
implying that TRPC1, 4, 5 positively influence membrane polarity in these cells.
TRPC channels in rat Purkinje cells mediate mGluR1 dependent induction of cerebellar
LTD (Chae, Ahn et al. 2012). TRPC3-containing channels are highly expressed in mouse
cerebellar Purkinje cells where they regulate slow excitatory postsynaptic current (sEPSC)
(Hartmann, Dragicevic et al. 2008). Interestingly, in addition to Gq/11-PLCβ signaling, activation
of TRPC3-containing channels in Purkinje cells was seen to require stimulation of phospholipase
D (PLD) (Glitsch 2010) and was insensitive to inhibition by protein kinase C (PKC), protein
kinase G (PKG) (Nelson and Glitsch 2012), and Ca2+ - the known negative regulators of TRPC3.
This was shown to be due to the expression of an alternative splice variant of TRPC3 that lacks
the TRPC3 CIRB site (Kim, Wong et al. 2012). Strikingly, a gain-of-function TRPC3 mutation
in mice leads to an impaired walking phenotype called the moonwalker syndrome (Becker, Oliver
et al. 2009). These mice exhibit cerebellar ataxia and Purkinje cell loss, demonstrating that
TRPC3-containing channels in cerebellar Purkinje neurons underlie the mechanism of mGluR1
evoked sEPSC and that this pathway is essential for cerebellar LTD and motor coordination.
Expression of TRPC6 peaks at P7–P14 in the rat hippocampus. Through the CaM Kinase
IV (CaMKIV) – cyclic AMP response element-binding protein (CREB) pathway, TRPC6
promotes dendritic spine and excitatory synapse formation (Tai, Feng et al. 2008, Zhou, Du et al.
2008). In hippocampal pyramidal neurons, brain-derived neurotrophic factor (BDNF) activates
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TRPC6 via the TrkB-PLCγ pathway. In developing neurons, mammalian target of rapamycin
(mTOR) activation causes translocation of GluA1, a subunit of the calcium conducting AMPA
receptor transiently expressed during early postnatal formation of glutamatergic synapses. Ca2+
influx through TRPC6 stimulates CaMKK followed by Akt phosphorylation which leads to
mTOR activation in these cells. Thus, TRPC6 activity is linked to increasing synaptic strength.
TRPC5 has also been shown to be upstream of mTOR in a similar manner (Fortin, Srivastava et
al. 2012). However, TRPC5 and TRPC6 have been shown to have converse effects on dendritic
growth. BDNF and neurotrophin-4 activation of TRPC6 through TrKB-PLCγ promotes dendritic
growth downstream of CaMKIV, whereas neurotrophin-3 stimulation of TRPC5 through TrkCPLCγ inhibits dendritic growth downstream of CaMKIIα (He, Jia et al. 2012). Similarly, TRPC4
signaling downstream of Gi/o stimulation in neurons, which is currently under investigation, may
have cross-talk with both TRPC5 and TRPC6 functions.

1.7.2 TRPCs in the cardiovascular system
Calcium signaling is central to normal heart function and signaling abnormalities that
underlie cardiac arrhythmias, hypertrophy and heart failure. In normal heart function, Ca2+
channels are responsible for the initiation and modulation of cardiomyocyte contractility,
regulation of vascular tone via regulation of vascular smooth muscle cell (VSMC) contractility
and permeability of endothelial cells (ECs). As transducers of both ROCE and SOCE, TRPCs
play significant roles in these processes.
ECs lining the blood vessel wall control permeability between blood and tissues, regulate
VSMC contractility, participate in immune responses and regulate angiogenesis. [Ca2+]i signaling
is central to all of these processes. Ca2+ influx through TRPCs has been implicated in endothelial
20

barrier function – increased Ca2+ influx increases endothelial permeability (Cioffi, Lowe et al.
2009, Cioffi, Barry et al. 2010, Ahmmed and Malik 2005). Specifically, for TRPC1, upon
stimulation with thrombin, the small GTPase RhoA can drive IP3R interaction with TRPC1 at the
plasma membrane of ECs, leading to an increase in SOCE, with resultant increase in endothelial
permeability (Mehta, Ahmmed et al. 2003). In TRPC4-/- mice, defects in microvascular
permeability, SOCE in ECs and endothelium-dependent vasorelaxation have been observed but a
direct effect on VSMC function has not been seen (Tiruppathi, Freichel et al. 2002, Ahmmed and
Malik 2005). Additionally, in the TRPC4-/- mice, ROCE in aortic ECs and the vasorelaxation of
aortic rings induced by acetylcholine is reduced (Freichel, Suh et al 2001).
In VSMCs, TRPC6 contributes to ROCE in response to α1-adrenergic receptor and
vasopressin receptor activation and has also been identified as a stretch sensor in myogenic tone
regulation (Guibert, Ducret et al. 2008, Sharif-Naeini, Folgering et al. 2010). In bovine aortic
ECs, TRPC6-mediated Ca2+ influx is obligatory for the inhibitory actions of LPC on cell
migration. The mechanism of LPC-induced inhibition of cell migration is an excellent illustration
of TRPC determined spatiotemporal Ca2+ signaling and crosstalk between different TRPC
isoforms. LPC activates TRPC6 to transiently increase Ca2+ influx which triggers plasma
membrane localization of TRPC5. TRPC5 activity then gives a prolonged Ca2+ influx that inhibits
EC migration (Chaudhuri, Colles et al. 2008).
Several interesting observations have been made with dominant negative (dn) forms of
TRPCs. dnTRPC3, dnTRPC4 or dnTRPC6 mice were found to be partially protected from loss of
cardiac function following long-term pressure-overload. Additionally, dnTRPC4 inhibited the
activity of native TRPC3, 6, 7 subfamily in the heart, demonstrating that the two subfamilies
(TRPC1, 4, 5 and TRPC 3, 6, 7) can function in coordination (Wu, Eder et al. 2010).
21

TRPC expression in the sino-atrial node pacemaker cells underlies SOCE which regulates
the pacemaker firing rate. Though specific isoforms were not identified, as Gd3+ inhibits this
activity TRPC1, 3, 6, 7 seem to be the likely candidates (Ju, Chu et al. 2007).
The most common pathway that has emerged from studies identifying TRPCs in
cardiomyocyte function is the TRPC-calcineurin-nuclear factor of activated T-cells (NFAT) axis,
which regulates gene transcription (Eder and Molkentin 2011, Kuwahara, Wang et al. 2006).
Calcineurin is a calcium-dependent serine-threonine phosphatase which activates NFAT, which
in turn binds to the promoter region of TRPC1, 3, 6, leading to a further increase in Ca2+ influx.
Therefore, there is a positive-feedback mechanism involving these three TRPC isoforms (Rowell,
Koitabashi et al. 2010). The positive feedback cycle can be triggered with an assortment of
stimuli. In hypoxic conditions, for example, hypoxia-inducible factor-1 alpha (HIF-1α) which is
a transcriptional regulator of hypoxic response, through an unknown mechanism upregulates
TRPC3 and TRPC6, leading to an increase in Ca2+-calcineurin signaling, setting off hypertrophy
(Chu, Wan et al. 2012). Additionally, in other contractile cells such as myofibroblasts, which can
differentiate into smooth muscle cells or fibroblasts, the TRPC6-calcineurin-NFAT pathway is
necessary for myofibroblast driven wound healing and tissue remodeling (Davis, Burr et al. 2012).
TRPC3 activity regulates cardiac fibroblast proliferation and differentiation. Atrial
fibrillation triggers increased expression of TRPC3 and causes TRPC3-dependent enhancement
of fibroblast proliferation and differentiation (Harada, Luo et al. 2012). In cardiomyocytes, it is
known that insulin increases DAG concentration in the lipid bilayer (Okumura, Matsui et al.
1996). Consequently, in addition to increased levels of TRPC3 expression, increased TRPC3
activity with application of insulin is also seen (Fauconnier, Lanner et al. 2007). TRPC3 activity
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triggered NFAT translocation to the nucleus and gene expression, however, require PKC
dependent phosphorylation of TRPC3 (Poteser, Schleifer et al. 2011).
Whether expression of multiple TRPC isoforms in the same cells indicates only
redundancy or can also lead to functionally significant crosstalk remains an open question. Several
studies, however, indicate that both modalities are viable in VSMCs: Endothelin-A receptoroperated TRPC1, 5, 6 are mediated by class I phosphoinositide 3-kinases γ (PI3Kγ) and TRPC3,
7 by class II/III PI3K isoforms. Importantly, receptor-activated and constitutively active PI3Kγmediated pathways inhibit TRPC3, 7 activation (Shi, Ju et al. 2012b). Heteromerization of TRPC1
with TRPC5 confers some of the sensitivity of TRPC1 to TRPC5 in mouse VSMCs. These
TRPC1/5 heteromeric channels are activated by PKC, PI-4,5-P2, PI-3,4,5-P3 (Shi, Ju et al.
2012a). In VSMCs from human veins, oxidized phospholipids can activate TRPC1/5 in a Gi/o
dependent manner and enhance cell migration without observable Ca2+ release in the cells (AlShawaf, Naylor et al. 2010). In mesenteric artery smooth muscle cells, angiotensin activation of
TRPC1/5 inhibits TRPC6 activity in a Ca2+ and PKC phosphorylation dependent manner (Shi, Ju
et al. 2010).

1.7.3 TRPCs in the pulmonary system
In pulmonary function Ca2+ signaling controls VSMCs and ECs to regulate the rate of
blood-oxygen exchange as well as responses to inflammation arising from exposure to allergens.
Several TRPC isoforms influence these functions.
In pulmonary ECs, more is known about the role of TRPC4 than other isoforms. Studies
so far have focused on the role of TRPC4 in the modulation of endothelial permeability. Lung
ECs from TRPC4-/- mice show impairment in actin stress fiber formation and reduced cell
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retraction in response to thrombin stimulation. The increase in lung microvascular permeability
in response to thrombin receptor activation is absent in TRPC4-/- mice (Tiruppathi, Freichel et al.
2002). Plus, TRPC1 and TRPC4 can interact with STIM1 to form functional SOCE channels
necessary for mediating the disruption of the endothelial barrier (Sundivakkam, Freichel et al.
2012). Also, TRPC3 and TRPC4 can heteromerize to form a redox sensitive channel (Poteser,
Graziani et al. 2006), imparting a redox sensitive modulatory capacity for endothelial barrier
function.
It has been suggested that a complex of Orai1, STIM1 and TRPC1 is responsible for SOCE
in PASMCs (Ng, McCormack et al. 2009, Ng, Airey et al. 2010). Expression of TRPC1 and
TRPC4 is enhanced in pulmonary arteries of hypertensive rats and is associated with the
development of hypertension (Liu, Zhang et al. 2012). As in the case with cardiovascular smooth
muscle cells, the role of TRPC4 is PASMCs is not well understood. However, one study showed
that low levels of extracellular ATP and CREB protein can upregulate TRPC4 in PASMCs to
promote cell proliferation (Zhang, Remillard et al. 2004).
TRPC1 can form store-operated channels in pulmonary endothelial cells and induce cell
shape remodeling via Ca2+-induced changes in the actin cytoskeleton (Moore et al. 2013,
Kwiatek, Minshall et al. 2006). TRPC1 is not active in normal airway smooth muscle cells
function. It can however mediate signaling in asthmatic conditions (Xiao, Zheng et al. 2010).
TRPC1 signaling in lymphocytes increases inflammation, leading to lung hyper-responsiveness
in response to allergens (Yildirim, Carey et al. 2012). TRPC3 regulates resting membrane
potential, intracellular calcium and consequently asthma-evoked membrane depolarization and
airway hyper-responsiveness. High TRPC3 expression in tumor cells has been considered as an
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independent predictor of better prognosis for patients with lung adenocarcinoma (Saito, Minamiya
et al. 2011).
In conditions of hypoxia, constriction of arteries in response to low oxygen levels leads to
redistribution of blood to better ventilated areas to optimize oxygenation. TRPC6 plays a
significant role in the Ca2+ influx regulated arterial constriction (Fuchs, Dietrich et al. 2010,
Fuchs, Rupp et al. 2011). Oxygen sensing enzymes such as P450 convert arachidonic acid to
epoxides and increase TRPC1 and TRPC6 expression (Liu, Wang et al. 2011). Caveolin-1
interacts with TRPC1 and IP3R and enables TRPC1-IP3R association in caveolae upon agonist
stimulation to regulate SOCE in ECs (Sundivakkam, Kwiatek et al. 2009). A gain-of-function
TRPC6 mutation primes PASMCs to an exaggerated response to transcription factor NFB which
activates cellular responses to stress. This increases the risk to the development of pulmonary
arterial hypertension (Hamid and Newman 2009). Development of pulmonary hypertension has
also been identified downstream of TRPC6 upregulation which contributes to increased PASMC
proliferation (Yu, Keller et al. 2009). TRPC6 has a prominent role in the development of chronic
obstructive pulmonary disease where it modulates inflammatory signals in various cell types
including mast cells, eosinophils and lymphocytes (Banner, Igney et al. 2011). Particularly, loss
of TRPC6 reduces airway response to allergen exposure (Sel, Rost et al. 2008. TRPC6 and cystic
fibrosis transmembrane conductance regulator are functionally coupled in airway epithelial cells
and abnormal Ca2+ signaling in cystic fibrosis arises with loss of this coupling (Antigny, Norez et
al. 2011). In lung ECs, TRPC6 contributes as an essential factor behind the development of edema
(Samapati, Yang et al. 2012, Weissmann, Sydykov et al. 2012). PTEN associates with TRPC6 to
target it to the plasma membrane and the PTEN-TRPC6 complex leads to increase in endothelial
permeability and promotes angiogenesis (Kini, Chavez et al. 2010).
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1.7.4 TRPCs in kidneys
Amongst several ion channel families that are involved in filtration, secretion and
resorption processes in the kidney, TRPCs have been identified to have significant roles as
modulators of Ca2+ signaling in normal renal function as well as disease states. Autosomal
dominant poly-cystic kidney disease (ADPKD) is an inheritable disorder primarily associated
with mutations in two genes PKD1 and PKD2, which ultimately lead to formation of clusters of
cysts in the kidneys. This condition leads to abnormalities in cell growth, fluid secretion, and
extracellular matrix along with further complications. The TRPC3, 6, 7 subfamily is again
prominent: association of TRPC3 and TRPC7 with mutant PKD-2 in kidneys enhances ROCE,
which leads to abnormal cell growth (Miyagi, Kiyonaka et al. 2009). Sparse evidence also links
TRPC3 to basal and pathophysiological renal conditions: In the renal nephron ATP release in
response to mechanical stress specifically activates TRPC3 in the apical membrane of principal
cells of the collecting duct (Goel and Schilling 2010). TRPC3 is elevated in kidney ECs obtained
from renal cell carcinoma patients with a history of hypertension, but not in those with normal
blood pressure (Thilo, Loddenkemper et al. 2009).
TRPC1/4 have also been shown to express in mouse glomerular mesengial cells though
their physiological roles have not been identified (Wang, Pluznick et al. 2004). As for
cardiovascular or pulmonary systems, the role for TRPC6 is prominent in renal physiology as
well. Podocytes create foot projections at glomeruli to form a structure called the slit diaphragm
where filtration of blood occurs. Abnormal function in podocytes leads to glomerular kidney
disease. TRPC6 is expressed in podocytes and its modulation promotes stability of the slit
diaphragm or adhesion of podocytes to the glomerular basement membrane, marking it as a key
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player in slit diaphragm function (Kim, Anderson et al. 2012). Increased levels of angiotensin II
(a peptide hormone that causes vasoconstriction) plus increase in blood pressure or shear stress
can lead to upregulation of TRPC6 expression and engage angiotensin II receptor type 1 to
activate TRPC6 channels, leading to closing of the slit diaphragm (Nijenhuis, Sloan et al. 2011).
TRPC6 in glomerular mesengial cells is down-regulated with increased glucose levels in
conditions such as diabetes and the resultant decrease in ROCE through TRPC6 contributes to
impaired contractility in mesengial cells (Graham, Gorin et al. 2011). Conversely, insulin
increases the surface expression of TRPC6 channels in podocytes in a nitric oxide-dependent
manner as a response to maintain the stability of the glomerular filtration. However, in
contradiction to this model, TRPC6-/- mice show no corresponding loss of function and it is
believed that similar to the case of cardiovascular TRPC6, increase of TRPC3 expression
compensates for the loss of TRPC6 (Dietrich, Chubanov et al. 2010).
The TRPC6-calcinerurin-NFAT pathway seen in the cardiovascular system is also
prominent in renal cell types. Focal segmental glomerulosclerosis (FSGS) is a disorder inflicting
scarring and inflammation on a subset of glomeruli. Gain-of-function TRPC6 mutations P112Q,
R895C, and E897K result in increased NFAT-mediated transcription, increased actin
polymerization, giving rise to a rigid cytoskeleton, lowered cell motility and increased cell death
leading to FSGS (Dietrich, Chubanov et al. 2010, Wang, Jarad et al. 2010). However, TRPC6 has
not been shown to be exclusively responsible for kidney disorders and failure. Simultaneous
mutations in TRPC6 and in other targets are implicated in kidney failure arising from FSGS
(Dietrich, Chubanov et al. 2010).
TRPC isoforms can also differentially regulate cell fate: Active TRPC5 can induce Rac1
activation promoting cell migration in podocytes while TRPC6 activity triggers RhoA which
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inhibits cell migration. The TRPC5-Rac1 and TRPC6-RhoA signaling complexes are spatially
and functionally segregated and provide signaling crosstalk that ultimately modulates cell
migration (Tian, Jacobo et al. 2010).
1.8 Summary and experimental considerations
Native channels composed of TRPC4 subunits have been observed to be likely
heteromeric, associating with TRPC1 subunits more frequently than with TRPC5 or other TRP
isoforms. TRPC1 subunits, when heteromerized with other TRPC isoforms, act as negative
regulators reducing the conductance of TRPCx by ten-fold. TRPC4/TRPC1 currents are therefore
significantly small and, as their reversal potential is around 0 mV, are often not clearly
distinguishable from background currents of other endogenous conductances such as chloride
channels and ion transporters. Therefore, to identify biophysical mechanisms of TRPC4
activation, a heterologous expression system was used where TRPC4 overexpression produced
predominantly homomeric channels (based on the large observed conductance - in spite of
endogenous TRPC1 levels). Additionally, in the case of homomeric channels formed by TRPC4
and TRPC5, the characteristic signature of maximally activated currents through these channels
is a current-voltage (I-V) curve which is double rectifying – with a characteristic ‘dip’ in the
outward rectification between 40 mV to 60 mV of holding potential. Observing this distinct
signature of maximally activated TRPC4 and TRPC5 channels helps to eliminate contaminating
currents from other non-specific conductances.
In physiological conditions (in the caveolae of ECs or in neuronal dendritic boutons) it is
more likely that these channels are activated locally and sub-maximally. It is in these conditions
that the coincident signaling of Gi/o and Gq/11 would be of significance. At low levels of Gi/o
signaling, the channels would remain silent and might only be activated when Gi/o is supplemented
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with Gq/11 stimulation. However, delineating the contributions of each pathway would be difficult
due to the reasons of contaminating currents described above. Therefore, for a large part of this
study, strongly activated TRPC4 or TRPC5 currents were used for the characterization of their
activation mechanism(s).
While there are 11 known splice variants of TRPC4: TRPC4α, TRPC4β, TRPC4γ,
TRPC4δ, TRPC4ε, TRPC4ζ, TRPC4η, TRPC4θ, TRPC4ι, TRPC4κ (Plant and Schaefer 2003),
the isoforms TRPC4α and TRPC4β are most commonly found in rodents and humans (Mery,
Magnino et al. 2001, Schaefer, Plant et al. 2002). Therefore, I focused on the characterization of
murine TRPC4α and TRPC4β isoforms. Of these, TRPC4β, lacking the 84 amino acid PIP2 and
CaM binding site at the C terminus shows less PIP2- (and likely CaM-) dependent inhibition and
is therefore optimal for investigating the possible role of direct G protein interactions with the
channel. Therefore, a significant number of assays were conducted using the murine TRPC4β
isoform.
Throughout this study, the whole-cell patch clamp technique has been used
predominantly. This is because TRPC channels are regulated downstream of receptor signaling
and therefore there was a possibility that several cytoplasmic components were involved in the
channel activation mechanism. In more parsimonious experimental conditions, such as excised
patch clamp - the contributions of these components could, in principle, be observed directly.
Excised patches (inside-out mode, described in Methods, Ch. 2) were performed in the
expectation that G protein subunits might directly activate TRPC4 (similar to direct G protein
activation of GIRK channels). Also, if any other cytoplasmic components were necessary, they
could be added to the intracellular side subsequently. However, while single channel recordings
could be performed to isolate TRPC5 (Fig. 5) or TRPC4 activity, addition of purified subunits of
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G proteins directly to the inside-out patches did not result in an increase in activity (Fig. 6),
suggesting

that

there

could

be

additional,

previously

uncharacterized

cytoplasmic

components/conditions that are necessary for TRPC4 activation. Therefore, the whole-cell patch
clamp configuration was selected for a principal number of assays.

Figure 5. Excised patch clamp showing TRPC5 currents
a. In HEK293 cells stably expressing TRPC5, inside-out recordings were made using symmetric
solutions, i.e., the same solution was used on both sides of the patch. The solution consisted of (in
mM) 140 CsCl, 1 MgCl2, 10 HEPES and 500 nM free Ca2+ buffered with 10 mM EGTA at pH
7.4. b. 100 µM La3+ dissolved in the same solution was added to the extracellular side by gentle
pipetting in the vicinity of the patch pipette tip. c. P(open) was measured using Clampfit
(Molecular Devices) and plotted for traces recorded at – 60 mV holding potential.
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Figure 6. Inside-out patch clamp for TRPC4 currents
a.,b., In HEK293 cells stably expressing µ opioid receptor (µOR) and TRPC4β, inside-out
recordings were made using symmetric solutions as in Fig. 5. After recording basal currents at
the holding potential (Vh) of -100 mV, for upto 2 mins, 10 nM (final concentration) of purified G
protein subunits [kindly provided by Dr. L. Birnbaumer (NIH, NIESH) and Dr. C. Dessauer (UT)]
were added to the bath solution by gentle pipetting in the vicinity of the patch pipette tip. When
the storage buffers used to solubilize G proteins were added similar changes in activity were
observed (not shown). c. To verify viability of purified Gβ1γ2 protein subunits, HEK293 cells
were transfected with human GIRK2 cloned in a pIRES-EGFP vector. Similar ‘positive’ controls
for Gαi/o were unavailable. Solutions used to record GIRK2 currents consisted of: 140 mM KCl,
5 mM NaCl, 1 mM EGTA, 1 mM MgCl2, 10 mM HEPES (pH 7.2) (bath solution – luminal side),
5 mM KCl, 140 mM NaCl, 2 mM CaCl2, 1 mM MgCl2 and 10 mM HEPES (pH 7.4) (pipette
solution – extracellular side). Similar to b., protein containing solution was added to the excised
patch after 2 mins of recording basal activity. d. Open probability (NPo) for patches from cells
expressing TRPC4β was measured using Clampfit (Molecular Devices) (n = 25 - 40). In the
control condition an equal volume of recording solution without proteins or protein storage buffer
was applied.
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Chapter 2
Methods
2.1 Reagents, complementary DNA (cDNA) and mutations
(D-Ala2, N-MePhe4, Gly-ol)-enkephalin (DAMGO) was from Bachem Chemicals Co;
carbamylcholine (carbachol), heparin, ionomycin (IM), phorbol 12-myristate 13-acetate (PMA),
R59 022, RHC 80267, U73122, U73343 were purchased from Sigma-Aldrich; Fura-2 AM was
from TEFLabs. D-myo-inositol 1,4,5-trisphosphate (IP3, Na+ salt) and 1-oleoyl-2-acetyl-snglycerol (OAG) were from Cayman Chemical Co. Pertussis toxin (PTX) was from List Biological
Laboratories, Inc. cDNA constructs for mouse TRPC4β, TRPC4α, TRPC5, PLCδ1, µ opioid
receptor (µOR), and muscarinic receptors were in pIRES-neo, pIRES-hygro or PCMVSport6
vectors. cDNA for downward DAG sensor (Tewson, Westenberg et al. 2012) was obtained from
Montana Molecular. cDNA construct for DrVSP was kindly provided by Dr. Y. Okamura
(Okazaki Institute for Integrative Bioscience), Lyn-FRB and CFP-FKBP-Inp54p by Dr. T. Meyer
(Stanford University), PLCδ1-WT, PLCδ1-ΔXY, PLCβ2 WT by Dr. J. Sondek (University of
North Carolina), RhoA WT and mutants (L63 and N19) as well as C3 exoenzyme by Dr. J. Frost
(University of Texas Health Science Center at Houston). PLCδ1 mutant E341R/D343R was
created using the QuikChange mutagenesis method (Stratagene) and primers 5’GGCCCGTCCCAGCAGCGAAGCCTCAGGCATCGGCAGCC-3’,

and

5’-

GGCTGCCGATGCCTGAGGCTTCGCTGCTGGGACGGGCC-3’. Small interfering RNA
(siRNA) oligomers were designed based on previously characterized sequences (Thompson and
Shuttleworth 2011) (Díaz Añel 2007) (for PLCδ1 sense: 5’-CAACAAGAAUAAGAAUUCA-3’,
antisense:

5’-UGAAUUCUUAUUCUUGUUG-3’,
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PLCδ3

sense:

5’-

GCAGCUCAUUCAGACCUAU-3’, antisense: 5’- AUAGGUCUGAAUGAGCUGC-3’, PLCβ1
sense: 5’-AACAAUUCUCCUUUCGUUUGA-3’, antisense: 5’UCAAACGAAAGGAGAAUUGUU-3’, PLCβ3 sense:5’- CCUGUGGCCUCAAAUUCAA-3’, antisense: 5’ UUGAAUUUGAGGCCACAGG-3’) and synthesized by Sigma-Aldrich. Polyplus INTERFERin reagent
(Polyplus Transfection) was used to transfect siRNA (50 nM) into cells; the transfection was
repeated 48 hours later and cells used for western blotting and patch clamping assays after an
additional 24 hours. Polyethylenimine (PEI) transfection reagent was kindly provided by Dr. G.
Du (University of Texas Health Science Center at Houston).

2.2 Cell lines and cell culture
Human embryonic kidney 293 cells (HEK293) were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM; high glucose) supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 100 units/ml penicillin and 100 µg/ml streptomycin at 37°C, 5% CO2. Stable cell
lines that expressed µOR only, µOR plus TRPC4β, µOR plus TRPC4α, µOR plus TRPC5, and
muscarinic receptor subtype (M2R) plus TRPC4β were created and maintained by using antibiotic
selection pressure [hygromcin for µOR and M2R encoded in the pIRES-hygro vector, neomycin
for TRPC4 and TRPC5 constructs encoded in the pIRES-neo vector (Miller, Shi et al. 2011)]. For
experiments where transient expression was used, cells were transfected using Lipofectamine
2000 (Invitrogen) or PEI (Feng, Huang et al. 2014). For Lipofectamine 2000-based transfections
in a 1 mL volume of cell culture, 0.5 µg of cDNA was mixed with 50 µL of DMEM (without
FBS). Separately, 4 µL of Lipofectamine 2000 was mixed with 50 µL of DMEM (without FBS)
and both mixtures were left at room temperature for 10 minutes, following which the two solutions
were mixed by vortexing and then left at room temperature for a further 10 minutes. This mixture
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was then added to a freshly trypsinized batch of cells at ~ 90% confluence in a poly-L-ornthine
coated dish. Media were changed after 4 hours and the cells were used for experiments after 1620 hours. For PEI-based transfections (for a 1 mL volume), cells were seeded on poly-L-orntihine
coated dishes 24 hours prior to transfection. cDNA (0.5 µg) was mixed with 50 µL of sterile NaCl
(0.15 M) and 4 µL of PEI reagent. The mixture was vortexed and left at room temperature for 10
mins, followed by addition to the cells containing dish. Cells were used for experiments after 1620 hours.

2.3 Patch clamp electrophysiology
Cells were seeded on 12-mm coverslips coated with poly-L-orntihine between 4-16 hours
before whole-cell recordings. Transiently transfected cells were identified by the green
fluorescence from the expressed enhanced green fluorescent protein (EGFP) encoded in the
plasmid for the protein of interest or the co-transfected pEGFP-N1 vector. Recording pipettes
were pulled from micropipette glass (Sutter Instruments) to 3-5 MΩ when filled with a pipette
solution containing (in mM): 140 CsCl, 1 MgCl2, variable ethylene glycol tetraacetic acid (EGTA)
or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), variable CaCl2, and 10
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), buffered to pH 7.2 with CsOH and
placed in the bath or extracellular solution (ECS) containing (in mM): 140 NaCl, 5 KCl, 2 CaCl2,
1 MgCl2, 10 glucose, and 10 HEPES, buffered to pH 7.4 with NaOH. Specific EGTA, BAPTA,
and free Ca2+ concentrations in the pipette solutions are explained in figure legends. Ca2+-free
external solutions had 0.2 mM EGTA added and CaCl2 omitted. Note, the use of NaCl in the bath
solution was very important for results reported here. Several previous studies used Cs+-based
bath solutions, which strongly enhance TRPC4 currents and tend to mask the strict requirements
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of channel activation on Gi/o and PLC pathways (Zholos, Zholos et al. 2004, Jeon, Hong et al.
2012, Kim, Jeon et al. 2013).
Isolated cells were voltage-clamped in the whole-cell or outside-out mode using an Axon
200B amplifier and 1440A Digitizer (Molecular Devices). Currents were acquired at 2 kHz. For
whole-cell recordings, a membrane test pulse was applied every 10 s to test for membrane
resealing. Cells that resealed were eliminated from analysis. As Ca2+ is a key modulator in these
studies, to ensure that external Ca2+ did not contaminate recordings, all patch-pipettes were firepolished and cells which retained membrane seal resistance > 1 GΩ were used. Cells were
continuously perfused with the bath solution through a gravity-driven multi-outlet device with the
desired outlet placed ~50 µm away from the cell being recorded. Drugs were diluted to the final
concentration in the bath solutions and applied to the cell at the rate of ~ 0.2 mL/min except where
added through the patch pipette after dilution in the pipette solution. Intracellular dialysis was
used for U73122 and U73343 to avoid the potential electrophilic effect of U73122 on reactive
cysteines at the outer mouth of the P-loop (Otsuguro, Tang et al. 2008, Xu, Sukumar et al. 2008).
Outside-out patches were performed using patch pipettes demonstrating 5-7 MΩ
resistance in solution. Cells were patched in the whole-cell configuration after which, with the
help of the coarse-movement setting on the micromanipulator, the patch pipettes were quickly but
gently pulled away diagonally above and across the cell so that the final position of the pipette tip
(along with the pulled membrane) rested a few millimeters on the side of the cell which was
opposite to the side from which the cell was initially approached by the pipette. This procedure
was followed as it was noted that pulling the patch away from the cell back towards the side from
which the cell was initially approached by the pipette often resulted in a significantly larger
section of the membrane tearing away along with other internal components of the cells - resulting
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in a suboptimal patch (with leaky currents and was prone to collapse during the experiment).
Pulling the patch across the cell, instead, gave stable patches. After pulling, the patch was allowed
to stabilize for upto 60 seconds. The patch resistance was > 1 GΩ.
Inside-out patches were performed using patch pipettes demonstrating 7-8 MΩ resistance
in solution. In this case, as opposed to the procedure used for outside-out patches, it was noted
that pulling the patch pipette vertically upwards from the cell resulted in a higher success of
patches that showed >1 GΩ in resistance. Solutions to the luminal side were then either added via
pipetting or via a gravity driven perfusion system.
Patch clamp recording data were analyzed using Clampfit (Molecular devices). For
visualization, whole-cell and outside-out records were filtered at 25 Hz with a high-pass 8-pole
Bessel filter. Inside-out records were filtered at 200 Hz.
The sodium acetate (NaAc) gradient method was applied and calibrated using 10 µM
nigericin in KCl solutions and the proton sensitive dye BCECF (2',7'-Bis-(2-Carboxyethyl)-5(and-6)-Carboxyfluorescein, Life Technologies) in its free acid form (calibration method is
described in further detail in the figure legend of Fig. 40). Briefly, patch-pipette solution contained
(in mM): 140 CsCl, 5 NaAc, 1 MgCl2, 0.05 EGTA, and 10 HEPES, pH 7.2. Bath solutions
contained (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 glucose, and 10 HEPES with equal
molar replacement of NaCl by 7.9 NaAc (for pHi = 7.2), 12.6 NaAc (for pHi = 7.0), 39.48 NaAc
(for pHi = 6.5), 70 NaAc (for pHi = 6.25), 100 NaAc (for pHi = 6.1), 125.4 NaAc (for pHi = 6.0).
Induced pH was calculated based on the formula:
log
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Solutions were allowed to dialyze into cells for 5 minutes to allow for complete replacement of
endogenous intracellular buffers before start of recordings. External buffers corresponding to
different pHi values to be induced were then applied for 30 seconds before receptor activation.

2.4 Calcium and DAG imaging
HEK293 cells heterologously expressing TRPC channels were seeded on 15-mm
coverslips coated with poly-L-orntihine between 4-16 hours before loading with 2 µM Fura2-AM
+ 0.01% F-127 at 37°C in the cell culture media for 40 minutes, after which the media were
replaced with ECS (described in 2.3). Alternating excitation wavelengths at 340 nm and 380 nm
were provided using the Sutter lambda-10B Smartshutter system controlled by Incytim2 software
(Intracellular Imaging). Cells were visualized at a magnification of 20X or 40X on a Nikon TE200
microscope. Fluorescence images from emission at 520 nm were taken using a Basler Scout
camera at the rate of 20 frames per minute. Drugs were applied via perfusion at the same rate as
for patch clamp experiments. For DAG measurements, a GFP-based ‘Downward DAG sensor’
(Montana Molecular) containing cDNA was transfected into cells and after 16-20 hours imaged
with 490 nm excitation and 535 nm emission using Incytim1 software (Intracellular Imaging).

2.5 Immunoblot
Cells were washed with ice-cold phosphate-buffered saline (PBS) followed by harvesting
in a RIPA lysis buffer containing: 10 mM Tris-HCl, 140 mM NaCl, 1 mM EDTA, 1% Triton X100, 0.1 % SDS, 0.1% sodium deoxycholate and protease inhibitors (Roche) (pH 7.4). Proteins
were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to polyvinylidene difluoride (PVDF) membrane (Thermo Scientific). The membrane
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was blocked with a blocking buffer: 5% milk and 0.1% Tween-20 in PBS (pH 7.4) for 12-16 hrs
with primary antibodies with the following dilution: rabbit anti-TRPC4 (1:500, 781EB affinity
purified (Meissner, Obmann et al 2011)), anti-PLCδ1 (1:1000, Thermo Scientific), anti-PLCδ3
(1:1000, Santa Cruz), anti-PLCβ1 (1:1000, Santa Cruz), anti-PLCβ3 (1:1000, Santa Cruz), mouse
anti-actin (1:5000, MP Biomedicals). After several washes with washing buffer (0.1% Tween-20
in PBS), the membrane was exposed to horseradish peroxidase-conjugated secondary antibodies
(1:10,000, Roche) for 30 minutes. After extensive washes with the washing buffer, the
immunoblots were visualized by exposure to an enhanced chemiluminescent susbtrate (Thermo
Scientific).

2.6 Glutathione S transferase (GST) pull down assays
Mouse TRPC4α amino acids 615-974 and 765-974 were cloned in-frame into the pGEX4T-1 vector for expression of GST-TRPC4 fusion proteins. Protein expression in E. coli BL21
was induced at O.D. 0.6 – 0.8 with 0.2 mM isopropyl-d-thiogalactoside for 4 h at 37 °C. The cells
were subsequently collected by centrifugation and resuspended in a buffer composed of: 10 mM
Tris–HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA and cOmplete protease inhibitor cocktail (Roche)
on ice. Following addition of 200 µg/mL of lysozyme and incubation on ice for a further 15
minutes, DTT (final 5 mM) and Sarkosyl (final 1%) were added and this was followed by
incubation on ice for a further 15 minutes. The samples were sonicated until clear and supernatant
was collected after centrifugation at 14000 rpm for 15 min at 4 °C. For every 360 µL of
supernatant, 40 µL 20% Triton X-100 was added along with 50% gluthathione sepharose bead
slurry (Life Technologies). Proteins were allowed to interact during rotation at room temperature
for 30 minutes and subsequently collected by centrifugation at 5000 rpm for 5 mins. The beads
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were washed 4 times with a buffer containing 0.5 % NP-40, 1 mM EDTA, 20 mM Tris, pH 8.0,
and 150 mM NaCl. Proteins were extracted by addition of Laemmli buffer containing βmercaptoethanol.

2.7 Surface biotinylation
HEK293 cells stably expressing µOR and TRPC4β were cultured on poly-L-ornithine
coated dishes 12 hours prior to transfection with desired cDNA using PEI. At 24 hours after
transfection, the cells were washed 2 times with ice-cold PBS, followed by incubation with 0.5
mg/mL Sulfo-NHS-S-S-Biotin (Pierce) for 30 min on ice. Unreacted biotinylation reagent was
washed quickly and gently with PBS containing 100 mM glycine. Cells were harvested in a lysis
buffer containing: 50 mM HEPES, 150 mM NaCl, 2 mM EDTA, 2 mM MgCl2, 1% Triton X-100,
and protease inhibitors (Roche) (pH 7.4). The homogenates were passed repeatedly through 23
gauge syringe needles to break DNA complexes and centrifuged at 20,000 g for 10 min at 4 °C.
Protein concentrations in the supernatant were measured using a BCA assay (Pierce) and 400 µg
of protein was incubated with 40 µL of 50% NeutraAvidin agarose (Pierce) in a total volume of
300 µL with PBS for 1 hr at room temperature with rotation. After NeutraAvidin agarose was
washed 6 times with PBS + 0.5% Triton X-100, bound proteins were eluted with SDS sample
buffer by heating in the presence of 1% β-mercaptoethanol at 55 °C for 5 min. Total protein and
isolated biotinylated proteins were run on SDS-PAGE gels and immunoblotted for TRPC4 and
actin.
2.8 Statistical analysis
Data are expressed as means ± S.E.M, and statistical analysis was performed using
Student’s paired or unpaired t-test, or ANOVA in Graphpad Prism. Differences were considered
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significant when p values were < 0.05 by paired or unpaired t test or by One-way ANOVA with
Newman-Keuls post-hoc test where indicated.

2.9 Graphics and data visualization
Illustrations were created in Microsoft PowerPoint. Data were processed and visualized in
Clampfit (Molecular Devices), Origin (Origin Labs), Prism (Graphpad) and Microsoft Excel.
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Chapter 3
Gi/o and PLCδ1 are necessary for TRPC4 activation

3.1 Introduction
Of the large mammalian TRP superfamily, the Canonical TRP members (TRPC1-7) are
closest in homology to the prototypical Drosophila TRP. Like the fly TRP, TRPC channels are
activated downstream of receptors that signal through PLC (Venkatachalam and Montell 2007).
In both heterologous and native systems, the Gq/11-PLCβ pathway has most commonly been used
to activate TRPC channels. Recent studies, however, also suggest a role for Gi/o proteins in the
activation of TRPC4/C5 (Jeon, Lee et al. 2008, Otsuguro, Tang et al. 2008, Kim, Kwak et al.
2014).
TRPC4 has been implicated in the regulation of microvascular permeability (Tiruppathi,
Freichel et al. 2002), dendritic neurotransmitter release (Munsch, Freichel et al. 2003), intestinal
cholinergic neurogenic contraction and motility (Tsvilovskyy, Zholos et al. 2009), neurite
extension (Weick, Austin Johnson et al. 2009), epileptiform burst firing and seizure-induced
neurodegeneration (Phelan, Mock et al. 2012, Phelan, Shwe et al. 2013). The channel mediates
Na+ and Ca2+ influx, causing membrane depolarization and [Ca2+]i elevation, which in turn alter
cell function (Tian, Thakur et al. 2013). Though advances have been made in demonstrating
TRPC4 channel activation under Gi/o and/or PLC stimulation, as well as its dependence on [Ca2+]i,
a precise description of signaling events underlying the mechanism of TRPC4 activation remains
elusive.
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In this study, I distinguished between Gq/11 and Gi/o pathways by using Gq/11-coupled
muscarinic and Gi/o -coupled μ opioid receptors (µOR), for their contributions to TRPC4
activation. I uncovered a strict dependence on Gi/o proteins and the PLC pathway. I focused on
constituents of PLC signaling that cooperate with Gi/o to activate TRPC4 and discovered a
necessity for PLCδ1, a PLC isoform co-regulated by Ca2+ and PIP2. My findings suggest that
TRPC4 channels are tightly regulated by coincident signaling from Gi/o and PLCδ1 stimulation
with the latter contributing significantly to the Ca2+ dependence and PIP2 regulation of channel
opening.

3.2 Results
3.2.1 TRPC4 activation requires coincident Gi/o stimulation and PLC activity
TRPC channels are commonly believed to be activated downstream from PLC stimulated
by Gq/11-coupled receptors or RTK (Venkatachalam and Montell 2007). When overexpressed in
HEK293 cells, both Gq/11- and Gi/o-coupled muscarinic receptors have been used to trigger TRPC4
currents (Kim, Kwak et al. 2014). However, in spite of the presence of endogenous Gq/11-coupled
muscarinic receptors (Fig. 7), muscarinic agonist, carbachol (CCh, 10-100 µM) elicited no or very
small currents in cells that stably co-expressed µOR (Miller, Shi et al. 2011) with either TRPC4β
or TRPC4α (Fig. 8a, 11a, 13).
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Figure 7. Ca2+ responses elicited by exogenously expressed µOR and endogenous muscarinic
receptors in HEK293 cells
Stable µOR-expressing cells were seeded on glass coverslips and loaded with Fura-2. Cells were
imaged for fluorescence ratio changes when excited alternately at 340 and 380 nm and challenged
with DAMGO followed by DAMGO + CCh as indicated over representative traces in a. Only few
cells responded to DAMGO, but all cells responded to CCh with fluorescence ratio (F340/380)
increases. Integrated ratio changes over a period of 60 sec (area under the curve) for individual
cells are shown in b. n = 4 coverslips with a total of 177 cells. **** p < 0.0001 by paired t test.
These data also show that the HEK293 cells endogenously express Gq/11-coupled muscarinic
receptors that respond to CCh to elicit robust [Ca2+]i increase.
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Subsequent addition of µ agonist, DAMGO (1 µM), caused robust currents, with currentvoltage (I-V) relationships typical for TRPC4/C5, such as a negative slope between 10 to 40 mV
and outward rectification at more positive potentials (Obukhov and Nowycky 2004, Plant and
Schaefer 2005, Kim, Kwak et al. 2014). The near linear I-V relation at negative potentials
indicates very strong channel activation (Obukhov and Nowycky 2004, Plant and Schaefer 2005).
Consistent with µOR being Gi/o-coupled, the currents were abolished by treatment with PTX (Fig.
8a, Fig. 13).
Interestingly, although CCh did not evoke TRPC4 currents via endogenous receptors,
overexpressing Gq/11-coupled M1, M3, or M5 muscarinic receptor (MnR) with TRPC4 allowed
CCh to induce such currents, which, much to our surprise, was also blocked by PTX (Fig.8b-e,
Fig. 9). Therefore, all overexpressed MnRs seem to activate TRPC4 via Gi/o proteins. By contrast,
I found that TRPC5 activation was only partially blocked by PTX when stimulated via either
endogenous or overexpressed M3R (Fig. 12, 13). Therefore, TRPC4 is more tightly regulated
than TRPC5 and it exhibits an absolute dependence on Gi/o proteins for strong channel activation,
although very weak activation might be achieved by stimulating only Gq/11.
My data thus show that obligatory action of Gi/o on TRPC4 was independent of receptor
subtypes. However, different receptors showed varied peak TRPC4 currents. Whether these
differences in peak currents occur because of variations in receptor expression levels, localization
or in G protein coupling is not known.
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Figure 8. TRPC4β activation is dependent on Gi/o signaling
a-c. Whole-cell currents in HEK293 cells that stably co-expressed µOR and TRPC4β (a)
untreated (upper panels) or treated with PTX (0.1 µg/ml, 16 hrs, lower panels). In b-e, cells also
transiently expressed M3R/ M1R/ M4R or M5R. Pipette solution contained 0.05 mM EGTA with
no added Ca2+ for all cells. CCh (100 µM) and DAMGO (1 µM) were added as indicated. Currentvoltage (I-V) relationships obtained from the voltage ramps at the indicated time points are shown
to the right of the time course. Note that in the absence of M3R, and in spite of saturating
concentration of CCh, CCh induced very small TRPC4β currents (a, and expanded I-V curves in
inset); PTX inhibited activation of TRPC4β regardless of overexpression of MnR. Summary data
are included in Fig. 13.
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Figure 9. Overexpressed Gq/11-coupled muscarinic receptors activate TRPC4β in a Gi/odependent manner in the absence of µOR
Whole-cell currents evoked by CCh (100 µM) in wild type HEK293 cells that transiently
expressed TRPC4β + M3R (a) or TRPC4β + M5R (b). Cells were either untreated (upper panels)
or treated with PTX as above (Fig. 8). Summary (means ± SEM) for CCh-evoked peak currents
at -60 mV is shown in c. n = 5 for each, * p < 0.05 vs -PTX by unpaired t test. Note the inhibition
of CCh-evoked currents by PTX even in the absence of µOR overexpression, ruling out the
possibility that an enhanced basal Gi/o turnover due to the expressed µOR might be responsible
for the Gi/o dependence. Pipette solution contained 0.05 mM EGTA with no added Ca2+ in all
cases.
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Figure 10. TRPC4α activation is dependent on Gi/o signaling
a & b. Whole-cell currents in HEK293 cells that stably co-expressed µOR and TRPC4α untreated
(upper panels) or treated with PTX (0.1 µg/ml, 16 hrs, lower panels). In b, cells also transiently
expressed M3R. Pipette solution contained 0.05 mM EGTA with no added Ca2+ for all cells. CCh
(100 µM) and DAMGO (1 µM) were added as indicated. I-V relationships obtained from the
voltage ramps at the indicated time points are shown to the right of the time course. Summary
data are included in Fig. 13.
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Figure 11. Endogenous currents in response to CCh and DAMGO in the absence of TRPC
overexpression
Stable cells expressing only µOR were untransfected (a) or transiently transfected with the cDNA
for M3R (b). In the absence of TRPC4, minimal whole-cell currents were induced by CCh (100
µM) and DAMGO (1 µM). Summary (means ± SEM) of peak current at -60 mV for a and b are
shown in c with the same data for PTX-treated TRPC4α from Fig.10 included for comparison. n
= 5 - 7.
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Figure 12. TRPC5 activation is partially dependent on Gi/o signaling
Whole-cell currents in HEK293 cells that stably co-expressed µOR and TRPC5 with transiently
expressed M3R, untreated (upper panels) or treated with PTX (0.1 µg/ml, 16 hrs, lower panels).
Pipette solution contained 0.05 mM EGTA with no added Ca2+. CCh (100 µM) and DAMGO (1
µM) were added as indicated. I-V relationships obtained from the voltage ramps at the indicated
time points are shown to the right of the time course. Summary data are included in Fig. 13.
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Figure 13. Comparison of basal and agonist-evoked peak currents in HEK293 cells that
co-expressed µOR with TRPC4β, C4α and C5 in the absence and presence of
overexpressed M3R
Summary of peak currents at -60 mV (means ± SEM) represented in Figs. 8, 10, 12 evoked by
CCh before (a) and after (b) subsequent addition of DAMGO for cells that co-expressed µOR
with TRPC4β, TRPC4α, or TRPC5. Cells that co-expressed M3R are indicated. Note that PTX
nearly completely inhibited TRPC4 but was only partially inhibitory to TRPC5. (n = 7 - 10, * p ≤
0.05, *** p ≤ 0.001 vs -PTX by t test). c. Summary (means ± SEM) of basal currents (0 - 30 sec
before agonist application) at -60 mV for the same cells included in a, as well as for those that
expressed µOR ± M3R without a TRPC as in Figure 11. Note that TRPC5, but not TRPC4,
exhibited marked basal currents. PTX significantly suppressed basal current in cells that coexpressed TRPC5 and µOR (* p < 0.05 vs -PTX by unpaired t test), but not in those that also
overexpressed the Gq/11-coupled M3R in addition to TRPC5 and µOR (ns, not significant).
Therefore, although the basal turnover of Gi/o proteins in µOR-expressing cells could contribute
to constitutive activation of TRPC5, it was extraneous when the turnover of Gq/11 proteins was
also enhanced by M3R overexpression.
Summary I: Gi/o signaling is necessary for maximal activation of TRPC4 but only
partially contributes to the activation of TRPC5.
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I then asked if Gi/o stimulation alone is sufficient to activate TRPC4. With [Ca2+]i weakly
buffered by 0.2 mM EGTA, DAMGO (1 µM) elicited currents in a large proportion (~71%,
designated as group 1 or Grp I) of TRPC4β/µOR-expressing cells (Fig. 14a, 15b). This proportion
was increased to ~100% if 0.05 mM EGTA was used to buffer internal Ca2+ (Fig. 14d,e).
Subsequent addition of CCh (10 µM) did not further enhance the currents (Fig. 14a, d).
It is unlikely that DAMGO caused TRPC4 activation via stimulating PLCβ. Although Gi/o
proteins activate certain PLCβ subtypes via Gβγ (Camps, Carozzi et al. 1992, Katz, Wu et al.
1992), this does not appear to be a prominent pathway in HEK293 cells, as DAMGO induced
Ca2+ transients only in ~2% of cells stably expressing µOR (Fig. 7). However, PLC activity
appeared to be required for DAMGO-evoked TRPC4β current, as it was inhibited by intracellular
dialysis of a PLC inhibitor, U73122, but not its inactive analog, U73343 (Fig. 16).
Also supporting the role of PLC in Gi/o -mediated TRPC4 activation, CCh enhanced the
probability of DAMGO to induce TRPC4β activation. Thus, all cells previously exposed to CCh
responded to DAMGO with robust currents (Fig. 15b); a small proportion of DAMGOirresponsive cells (Grp II) responded to subsequent CCh application with sizeable currents (Fig.
14b, 15b); all cells responded to co-application of DAMGO and CCh with large currents (Fig.
14c, 15b). Therefore, Gq/11-PLC activation greatly enhanced the ability of Gi/o-coupled receptors
to activate TRPC4.
Noticeably, although the maximal (peak) current amplitudes evoked by DAMGO alone and
DAMGO + CCh were similar (Fig. 15b), the rate of current development was significantly slower
by DAMGO alone than DAMGO + CCh (Fig. 15c). DAMGO-evoked currents exhibited biphasic
kinetics – an initial slow phase followed by a fast-rising phase (Fig. 14), similar to that reported
previously for TRPC5 (Obukhov and Nowycky 2004). Co-application of CCh eliminated the slow
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phase (Fig. 14b, 15c). Quantification of time to 90% peak current (T90) revealed a significant
decrease by >20 s with DAMGO + CCh. This was also seen in cells that co-expressed Gi/o -coupled
M2R and TRPC4β which allowed simultaneous Gq/11 and Gi/o stimulation by CCh, leading to fast
current development (Fig. 15a,c), with similar peak amplitudes as TRPC4β/µOR cells (Fig.
15a,b).
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Figure 14. Intracellular Ca2+ buffering strength strongly impacts Gi/o-mediated TRPC4
activation
a-c. Representative whole-cell current traces of HEK293 cells co-expressing TRPC4β and µOR.
Pipette solution contained 0.2 mM EGTA and no Ca2+. CCh (10 µM) and/or DAMGO (1 µM)
was added as indicated. I-V relationships obtained from the voltage ramps at the indicated time
points are shown to the right of the current traces. For DAMGO stimulation alone, cells were
divided into Group I (Grp I, a) and Group II (Grp II, b) for DAMGO-responsive and irresponsive,
respectively. Simultaneous application of DAMGO and CCh evoked currents in all cells (c).
Summary data are shown in Figure 15. d-e, Effect of intracellular Ca2+ buffering capacity on
DAMGO-evoked whole-cell currents. Pipette solutions contained 0, 0.05, 0.5, or 5 mM EGTA
with no added Ca2+. All tested cells (100%) responded to DAMGO at 0 and 0.05 mM EGTA. The
DAMGO-evoked current activation was blocked in 7 out of 12 cells with 0.5 mM EGTA, but
subsequent addition of CCh elicited the current. At 5 mM EGTA, no TRPC4 current was detected
in response to DAMGO or DAMGO plus CCh. Representative traces (d) and summary data (e)
for individual cells (circles) and means ± SEM (lines) for DAMGO-evoked peak currents at -60
mV are shown (n=12).
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Figure 15. Co-stimulation of Gq/11 and Gi/o pathways strongly enhances the probability and
rate of TRPC4 activation
a. Representative whole-cell current trace of HEK293 cells co-expressing TRPC4β and M2R
showed a rapid rise to peak current similar to currents induced in TRPC4β and µOR co-expressing
cells in Fig. 14a-c. Pipette solution contained 0.2 mM EGTA and no added Ca2+. b. Peak currents
at -60 mV induced by DAMGO and/or CCh as indicated for individual cells from Figure 14a-c
and 15a. Blue boxes and bars show means ± SEM. Note the clear segregation between Grp I and
Grp II cells in response to DAMGO alone was abolished by CCh. c. Summary of time the current
reached 90% peak (T90) for cells stimulated with DAMGO and/or CCh. ** p < 0.01, *** p <
0.001, **** p < 0.0001 by t test. Cell numbers are shown in parentheses.
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Figure 16. Concentration-dependent inhibition of DAMGO-induced TRPC4β currents by
U73122
Pipette solutions contained 0.05 mM EGTA and no added Ca2+ but were supplemented with
different concentrations of U73122 or U73343. DAMGO (1 µM) was applied extracellularly 5
min after establishment of whole-cell mode to allow sufficient drug dialysis. Shown are means ±
SEM (n = 5 each) for DAMGO-evoked peak currents at -60 mV.

Summary II: In addition to Gi/o stimulation, TRPC4 activation requires coincident
intracellular Ca2+ elevation and PLC stimulation, which enhances both the
probability and kinetics of current development.
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3.2.2 Reducing PIP2 level suppresses sustained TRPC4 activity but facilitates Gi/omediated channel activation
While physical interaction between Gi/oα subunits and TRPC4 C-terminus has been
suggested to underlie the mechanism of action of Gi/o (Jeon, Hong et al. 2012), the mechanism by
which PLC affects TRPC4 gating remains mysterious. PLC activation causes breakdown of PIP2,
generation of DAG and IP3, which activates IP3R on the endoplasmic reticulum (ER) membrane,
leading to elevation of [Ca2+]i (Berridge, Lipp et al. 2000). DAG activates TRPC3, C6, C7, but
not TRPC4/C5 (Hofmann, Obukhov et al. 1999, Okada, Inoue et al. 1999). IP3R may exert a
positive effect on activation of all TRPCs by competing with Ca2+-CaM for binding to TRPC
(Tang, Lin et al. 2001, Zhang, Tang et al. 2001, Vaca and Sampieri 2002). Incidentally, the CIRB
site, a conserved motif of about 30 amino acids on proximal C-terminus of TRPC (Tang, Lin et
al. 2001, Zhang, Tang et al. 2001, Zhu 2005), is also critical for Gi/oα effect on TRPC4 (Jeon,
Hong et al. 2012). Also, Ca2+ exhibits both positive and negative effects on some TRPC channels
(Kinoshita-Kawada, Tang et al. 2005, Ordaz, Tang et al. 2005, Gross, Guzman et al. 2009).
To define components of the PLC pathway critical for TRPC4 activation, I first examined
PIP2. Previously, PIP2 has been shown to inhibit activation of TRPC4α (Otsuguro, Tang et al.
2008), but prevent desensitization of TRPC4β (Kim, Jeon et al. 2013). Using zebrafish voltagesensitive phosphatase (DrVSP) to reduce PIP2 content without a concomitant hydrolysis, I
observed a marked depression upon phosphatase activation for TRPC4β currents evoked by both
DAMGO and DAMGO + CCh (Fig. 17), suggesting that Gi/o-mediated TRPC4β activation also
depends on PIP2. Therefore, either PIP2 itself or its hydrolysis product(s) may be essential for
continued TRPC4β activation.
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Figure 17. PIP2 depletion suppresses TRPC4 activation under maximal Gi/o–stimulation
Stable HEK293 cells co-expressing µOR and TRPC4β were transiently transfected with either a
control vector or cDNA encoding zebrafish voltage-sensitive phosphatase (DrVSP). Pipette
solution had 0.05 mM EGTA and no added Ca2+. a. Cells were held at -60 mV while
depolarization pulses (100 mV, 0.5 sec) were applied every 5 sec. DAMGO (1 µM) and CCh (10
µM) were applied as indicated. Note the decrease in current amplitude immediately following
each pulse in the DrVSP-expressing cell. Sections pointed by the arrowheads are expanded on left
with I0 (current before pulse) and I (current after pulse) indicated. No current depression was
detected in control cells or before DAMGO application in DrVSP-expressing cells. b. Time
courses of I/Io for control and DrVSP-expressing cells before and during stimulation by DAMGO
± CCh. n = 6 each. c. Summary of T50 and T90 by DAMGO. Although T90 did not reach statistical
significance, T50 values are different. The near doubling of T90 vs T50 in DrVSP-expressing cells
indicates monophasic current development, whereas in controls T50 and T90 values are close as
both occurred during the fast rising phase.

57

Noticeably, repeated PIP2 dephosphorylation by DrVSP abolished the slow phase of the
biphasic response to DAMGO (Fig. 17a). T90 was shortened but did not reach statistical
significance (p = 0.1); however, T50 was significantly shorter with DrVSP (Fig. 17c), suggesting
an acceleration of the initial phase and a likely slow down of the rapid rising phase.
Thus, reducing PIP2 may help initial current development. To test this possibility, I
conducted weak Gi/o stimulation using 30 nM DAMGO, which was insufficient to elicit current
in control cells. With DrVSP, the same stimulation induced TRPC4β current (Fig. 18). Similarly,
dephosphorylating PIP2 with rapamycin-induced membrane translocation of yeast inositol
polyphosphate 5-phosphatase, Inp54p (Komatsu, Kukelyansky et al. 2010) also facilitated
TRPC4β activation by weak µOR stimulation (Fig. 19).
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Figure 18. PIP2 depletion facilitates TRPC4 activation under subthreshold Gi/o –stimulation
a. Sub-threshold DAMGO concentration (30 nM) activated TRPC4β currents in DrVSPexpressing but not control cells. Subsequent addition of CCh (10 µM) led to robust current
development in the control cell. Depolarization pulses were applied at 10 sec intervals. b.
Summary of peak currents at -60 mV for experiments illustrated in a. * p < 0.05 vs controls by t
test.
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Figure 19. PIP2 depletion via Inp54P facilitates TRPC4 activation
Stable HEK293 cells co-expressing µOR and TRPC4β were transiently transfected with cDNA
for Lyn-FRB alone (as a control) or those for Lyn-FRB and CFP-FKBP-Inp54p together (to allow
rapamycin-dependent plasma membrane translocation of Inp54P). Rapamycin (1 µM) was
applied extracellularly 5 min before and maintained during whole-cell recordings. Pipette solution
contained 0.05 mM EGTA with no added Ca2+. a. Representative whole-cell currents in response
to a sub-threshold concentration of DAMGO (30 nM) and subsequent addition of CCh (10 µM)
in a control cell (upper panel) and a cell in which endogenous PIP2 level had been decreased via
dephosphorylation by Inp54p (lower panel). I-V curves obtained from the voltage ramps at the
indicated time points shown to the right of the time courses revealed typical TRPC4-like I-V
relationship. b. Summary (means ± SEM) of peak currents at -60 mV evoked by 30 nM DAMGO
and after subsequent addition of 10 µM CCh. Note, reducing PIP2 content by Inp54p not only
enhanced the probability of TRPC4β activation by weak Gi/o stimulation with the low
concentration of DAMGO but also decreased the overall current amplitude evoked by the costimulation of Gi/o and Gq/11 pathways (DAMGO + CCh). * p < 0.05, ** p < 0.01 vs control by
unpaired t test. Numbers of cells are shown in parentheses.
Summary III: Within the mechanism of PLC stimulation, which enhances the
probability and kinetics of TRPC4 activation, the depletion of PIP2 is an essential step.
PIP2 exerts a tonic inhibition on the channel. Therefore, activation of PLC releases
PIP2 inhibition on TRPC4 - facilitating the activation of channel. However, PIP2 also
supports TRPC4 function.
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3.2.3 Ca2+ improves the probability but not rate of Gi/o–mediated TRPC4 activation
The need for PIP2 to support TRPC4 current could reflect a dependence on its breakdown
product(s), among which IP3R activation and [Ca2+]i rise have been shown to support TRPC4/C5
function (Venkatachalam and Montell 2007). To determine if IP3R are involved in TRPC4
activation, I applied IP3R inhibitor, heparin (3 mg/ml), through intracellular dialysis and found
that most (7/10) cells failed to respond to DAMGO and subsequent application of CCh (10 µM)
(Fig. 20a-c).
However, addition of Ca2+ ionophore, IM (10 µM), rescued the response, with peak
currents similar to that activated by DAMGO in controls (Fig. 20b, c). IM causes ER Ca2+ release
without activating IP3R. At 10 µM, it also causes Ca2+ influx. Thus, increasing [Ca2+]i by IM
bypassed the IP3R requirement for TRPC4β activation. These results suggest that IP3R-mediated
ER Ca2+ release is an important part of the Gq/11-PLC pathway for TRPC4 activation.
A small number of heparin-treated cells (3/10) responded to DAMGO with peak
amplitudes comparable to controls (Fig. 20c). This could arise from either an incomplete block
of IP3R or IP3R-independent [Ca2+]i rise. Presumably, a triggering [Ca2+]i rise provided by IP3R
or other means could open a few TRPC4β channels, which would be followed by opening of all
channels in the cell through a positive-feedback mechanism due to the Ca2+ permeability of these
channels. This strong cytosolic Ca2+ dependence is supported by the finding that increasing the
intracellular Ca2+ buffering strength by higher concentrations of EGTA in the patch pipette
decreased the probability of DAMGO-evoked TRPC4β whole-cell currents (Fig. 14d,e). In
addition, increasing the EGTA concentration in the pipette solution also abolished DAMGOevoked TRPC4β currents in outside-out patches (Fig. 21a, b).
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Figure 20. IP3R-mediated Ca2+ release provides triggering Ca2+ to initiate TRPC4 activation
All cells stably co-expressed TRPC4β and µOR. a-c. Heparin suppressed the activation of TRPC4
by DAMGO ± CCh. Vehicle (Veh., a) or heparin (3 mg/ml, b) was infused into cells by pipette
dialysis for > 5 min before DAMGO (1 µM), CCh (10 µM) and IM (10 µM) were applied
extracellularly. Whole-cell currents and I-V curves showed lack of or very weak response to
DAMGO and DAMGO + CCh in a heparin-treated cell, but addition of IM rescued the response
(b). c. Peak currents at -60 mV induced by DAMGO ± CCh or IM as indicated for individual cells
treated or not by heparin. Note 3 cells were not inhibited by heparin. Blue boxes and bars show
means ± SEM. Cell numbers are shown in parentheses. ** p ≤ 0.01, by ANOVA.
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Figure 21. Ca2+ regulates DAMGO evoked TRPC4 currents
Strength of the intracellular Ca2+ buffer strongly affected DAMGO-evoked TRPC4 activation in
outside-out patches. a. DAMGO (1 µM)-evoked activation of TRPC4 currents were gradually
suppressed by increasing the EGTA concentration in the pipette solution, in which no Ca2+ was
added. b. Summary data (means ± SEM) for DAMGO-evoked peak currents in outside-out
patches at -60 mV (b). n = 5 – 7. Note, unlike the whole-cell currents shown in Fig. 14 d,e, CCh
(10 µM) did not facilitate the outside-out currents at 0.5 mM EGTA.
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Also, DAMGO evoked very small currents in whole-cell and no current in outside-out
patches when Ca2+ was removed from the bath solution (Fig. 22a, b), showing the importance of
continued Ca2+ influx to support Gi/o -mediated TRPC4 currents. The strong extracellular Ca2+
dependence was also seen in the presence of IM (either 1 or 10 µM) (Fig. 22c,d). In this case,
despite the [Ca2+]i increase induced by IM through mobilization of ER Ca2+ store, while Gi/o
signaling was activated by DAMGO (30 nM), sizeable biphasic TRPC4 current was not developed
until Ca2+ (2 mM) was added to the bath solution.
In Fig. 14b, d, CCh only increased currents in cells that failed to respond to DAMGO
alone, suggesting that the Gq/11-PLC pathway might provide the triggering Ca2+ via IP3R-mediated
ER Ca2+ release. To examine if a triggering [Ca2+]i rise was sufficient for TRPC4 activation, we
treated DAMGO-irresponsive (Grp II) cells with IM. All cells responded to IM, with the peak
amplitudes similar to that evoked by DAMGO in Grp I cells (Fig. 23b, d). By contrast, neither
IM alone nor IM + CCh induced discernible TRPC4β current (Fig. 23c, d). Subsequent
application of DAMGO to these cells gave robust currents, with peak amplitudes similar to cells
stimulated by DAMGO + IM irrespective to the sequence of drug application (Fig. 23d). These
results reinforce the idea that with Gi/o stimulation a triggering [Ca2+]i rise is also necessary for
TRPC4 activation. However, currents induced by DAMGO + IM still exhibited biphasic kinetics,
with T90 significantly longer than if CCh was included in the stimulation cocktail (Fig. 23c, e),
suggesting that IM treatment, or [Ca2+]i rise, did not completely reproduce the effect of Gq/11-PLC
stimulation for TRPC4 activation.
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Figure 22. Ca2+ influx supports continued TRPC4 activation
Removal of extracellular Ca2+ strongly suppressed DAMGO-evoked TRPC4 currents in outsideout (a) and whole-cell (b) patches. The pipette solution contained 0.05 mM EGTA and no added
Ca2+. A Ca2+-free extracellular solution containing 0.2 mM EGTA with no added Ca2+ (0 Ca2+)
replaced the regular extracellular solution containing 2 mM Ca2+ at the indicated time periods
while DAMGO (1 µM) was applied. The current decrease in 0 Ca2+ indicates a strong requirement
for a continuous supply of Ca2+, via Ca2+ influx, to maintain TRPC4 activity. Note that TRPC4
whole-cell current was weakly activated by DAMGO in 0 Ca2+ (dotted rectangle in b), but it
reached maximal activation only in the presence of external Ca2+. c, d, In the absence of
extracellular Ca2+, addition of either 1 µM or 10 µM IM was insufficient to facilitate the full
TRPC4 activation under subthreshold stimulation of Gi/o. Only addition of external Ca2+ permitted
the development of a biphasic current.
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Figure 23. Intracellular Ca2+ improves probability but not rate of Gi/o -mediated TRPC4
activation
All cells stably co-expressed TRPC4β and µOR. The pipette solution contained 0.2 mM EGTA
with no added Ca2+. IM (10 µM) was applied before DAMGO (1 µM) (a). In this case, IM caused
small increase in current, but the I-V curve was not typical of the TRPC4 currents. A significantly
larger current was evoked by stimulation with DAMGO. DAMGO-irresponsive cells (Grp II)
became activated in presence of IM (b), but IM ± CCh failed to elicit current until DAMGO was
introduced (c). d. Peak currents at -60 mV induced by DAMGO, CCh, and IM. Only Grp II cells
were further treated with IM. e. T90 for currents evoked by DAMGO + IM ± CCh. Cell numbers
are shown in parentheses. ** p ≤ 0.01, *** p ≤ 0.001 by t test.
To determine the [Ca2+]i needed to maximally activate TRPC4, we clamped free Ca2+
levels in pipette solutions using 10 mM BAPTA which also minimized Ca2+ fluctuations during
whole-cell recordings. With free [Ca2+]i clamped to 100 nM, neither DAMGO alone, nor
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DAMGO + CCh evoked TRPC4 currents (Fig. 24a). Increasing free [Ca2+]i to > 1 µM allowed
current development in response to DAMGO, with maximal current achieved at ~10 µM free
[Ca2+]i (Fig. 24b-d). Interestingly, DAMGO-evoked currents became smaller at > 50 µM free
[Ca2+]i, indicating a dual dependence on [Ca2+]i (Fig. 24d). Fitting the Ca2+-dependent changes of
TRPC4 currents with a biphasic Hill equation (Foskett, White et al. 2007) yielded an EC50 of ~12
µM and an IC50 of ~28 µM for Ca2+-dependent facilitation and inhibition, respectively, suggesting
a very narrow [Ca2+]i range for TRPC4 activation. Altogether, the above results demonstrate the
importance of [Ca2+]i rise in Gi/o -mediated TRPC4 activation; however, Ca2+ alone was
insufficient to recapitulate the facilitation by PLC on activation kinetics.
Another important observation was that a mere rise in [Ca2+]i was insufficient to facilitate
maximal TRPC4 activation, as 10 µM IM would deplete all intracellular calcium stores, but was
insufficient to facilitate activity (Fig 23a). Physiological level of extracellular calcium was
necessary even in the presence of IM (Fig 22c, d) or at ~10 µM free [Ca2+]i buffered with 10 mM
BAPTA (Fig 24, 25), suggesting that a Ca2+ influx process is essential for TRPC4 activity. It is
possible that this Ca2+ influx occurs via TRPC4 itself and is highly spatially localized.
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Figure 24. Bimodal regulation of TRPC4 activation by intracellular Ca2+
Whole-cell currents evoked by DAMGO ± CCh in cells dialyzed with pipette solutions containing
10 mM BAPTA with [Ca2+] (concentration of free Ca2+) clamped to 100 nM (a) and 10 µM (b).
I-V curves are shown for basal and DAMGO-evoked currents with [Ca2+]i clamped at 10 µM (c).
d. Summary of DAMGO-evoked peak currents at -60 mV for cells dialyzed with 10 mM BAPTA
and free [Ca2+]i clamped at indicated levels. Data points (n = 5 - 8) were fitted with the biphasic
Hill equation with the expected maximal peak current (PHill) set to be 2.4 nA, based on the average
peak current in response to DAMGO + IM obtained when [Ca2+]i was allow to fluctuate. The
estimated EC50 for Ca2+ facilitation was 12.2 µM, Hill 1.30; the estimated IC50 for Ca2+ inhibition
was 28.3 µM, Hill -1.68. Inset shows T90 of DAMGO-evoked currents with [Ca2+] in the pipette
solution clamped as indicated. Extracellular calcium was 2 mM. e, Negative control with a cell
that expressed µOR only and the pipette [Ca2+] clamped at 10 µM by 10 mM BAPTA. The leak
current developed under these conditions did not have the typical I-V relationship of the TRPC4
currents. f, Basal currents at -60 mV in cells that stably expressed TRPC4β + µOR or just µOR
dialyzed with pipette solutions containing indicated free [Ca2+]’s clamped by 10 mM BAPTA.
For TRPC4β/µOR cells, data were from same cells shown in d. For µOR only cells, n = 4 each
for <0.001 µM Ca2+ and 10 µM Ca2+. The results suggest that the enhanced basal currents at high
free [Ca2+]’s are unrelated to TRPC4.
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Figure 25. Dependence of TRPC4 currents on extracellular Ca2+ while [Ca2+]i was clamped
at 10 µM by BAPTA
a & b, The pipette solution had 10 µM free Ca2+ buffered by 10 mM BAPTA. Under whole-cell
mode, DAMGO (1 µM) was applied either in the Ca2+-free (a) or Ca2+-containing (b) extracellular
solution as in Fig. 22b. The solutions were then exchanged as indicated. Note the clear increase
in current amplitude upon reintroduction of the extracellular Ca2+, although the magnitude was
smaller than with the 0.05 mM EGTA buffer as shown in Fig. 22b. The removal of extracellular
Ca2+ also resulted in less suppression of DAMGO-evoked current than that shown Fig. 22b.

Summary IV: Intracellular Ca2+ elevation is necessary for Gi/o mediated TRPC4
activation. The Ca2+dependence is biphasic with an EC50 of ~12 µM and IC50 of 28
µM.
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3.2.4 PLCδ1 is involved in TRPC4 activation
Testing other components of the PLC pathway, I found no evidence for IP3, DAG, or PKC
to be involved in facilitating Gi/o-mediated TRPC4 activation even with the triggering [Ca2+]i rise
induced by IM (Fig. 26a-c). Interestingly, using a DAG sensor (Tewson, Westenberg et al. 2012),
I detected more robust DAG production induced by DAMGO + CCh in TRPC4β/µOR cells than
cells that expressed µOR alone (Fig. 26d), indicating that TRPC4β also strongly enhanced PLC
activity. A likely way for TRPC4 to enhance PLC function was by maintaining elevated [Ca2+]i
through Ca2+ influx since most PLC isoforms are Ca2+ sensitive and some directly activated by
Ca2+, e. g. PLCδ (Suh, Park et al. 2008). Thus, although the Ca2+ signal generated by PLC provides
the initial trigger for TRPC4 activation, the sustained [Ca2+]i elevation resulting from channel
activity also prolongs PLC stimulation, which may further supports continued TRPC4 function.
To test whether a specific PLC isoform is required for TRPC4 activation, I knocked down
PLC isoforms typically associated with Gq/11 and Ca2+ signaling in HEK293 cells (Atwood, Lopez
et al. 2011) using isoform specific siRNA. Intriguingly, knockdown of PLCδ1 but not PLCδ3,
PLCβ1 or PLCβ3 inhibited TRPC4 activation (Fig. 27a, b). To confirm the involvement of
PLCδ1, I expressed the Ca2+-insensitive, dominant-negative PLCδ1 mutant, E341R/D343R
(Murthy, Zhou et al. 2004) and observed a strong inhibition of TRPC4β (Fig. 28a, b) and
TRPC4α, but not TRPC5 (Fig. 29). Conversely, overexpression of wild-type PLCδ1 (but not
PLCβ1/β2) significantly reduced T90 of DAMGO-evoked TRPC4β current without affecting peak
amplitude (Fig. 28a-c). These results indicate that Ca2+-dependent PLCδ1 function is not only
necessary but also rate limiting for TRPC4 activation.
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Figure 26. Effects of other components of PIP2 hydrolysis on Gi/o -mediated TRPC4
activation
a-c. All cells stably co-expressed TRPC4β and µOR. Whole-cell currents were recorded (as
shown in a) with the pipette solution containing 0.05 mM EGTA with no added Ca2+. IM and
DAMGO (both at 1 µM) were applied extracellularly as indicated. Together with DAMGO,
phorbol-12-myristate-13-acetate (PMA, 1 µM), OAG (50 µM), or CCh (30 µM) were also
applied. Alternatively, DAG lipase inhibitor (RHC 80267, 50 µM) and DAG kinase inhibitor (R59
022, 50 µM) were co-applied extracellularly 5 min before- and maintained during- the whole-cell
recording (iDAGL/iDAGK), or IP3 (1 µM) was included in the pipette solution. However, none
of these treatments altered the peak currents (at -60 mV) elicited by IM and DAMGO (b). Only
CCh significantly reduced T90 (c). Summary data in b and c are means ± SEM for n = 5 - 7 cells.
* p < 0.05 by One-way ANOVA followed by Newman-Keuls post-hoc test. d. Concomitant
stimulation by DAMGO and CCh caused more DAG production in the presence of TRPC4β than
in its absence. A fluorescent downward DAG sensor was transiently transfected into stable cell
lines that expressed µOR alone or µOR + TRPC4β. DAG production was monitored as a decrease
in fluorescence detected using the standard filter set for rhodamine. Cells were stimulated by
DAMGO and CCh as indicated. Data are means ± SEM for 14 cells that expressed µOR and 10
cells that co-expressed µOR and TRPC4β.
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Figure 27. The involvement of PLCδ1 in Gi/o-mediated TRPC4 activation
a & b. siRNA knockdown of PLCδ1 inhibited TRPC4β currents. Stable HEK293 cells coexpressing µOR and TRPC4β were transfected with pEGFP-N1 or pEGFP-N1 + siRNA for
PLCδ1, PLCδ3, PLCβ1, or PLCβ3. The transfection was repeated after 48 hrs and cells analyzed
24 hrs later. The knockdown efficiency was analyzed by Western blotting (a). DAMGO and CChevoked whole-cell currents were measured as in Fig. 14d with the pipette solution containing 0.05
mM EGTA and no added Ca2+. Despite the incomplete knockdown, currents evoked by 1 µM
DAMGO alone and that with subsequent addition of 10 µM CCh were both significantly
decreased by the siRNA for PLCδ1 but not that for other PLC isoforms (b). Data are means ±
SEM for n = 13 cells for all data points. * p < 0.05 by One-way ANOVA followed by NewmanKeuls post-hoc test.
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Figure 28. PLCδ1 is necessary for DAMGO-evoked TRPC4 activation
Stable TRPC4β/µOR cells were transiently transfected with either a control vector or cDNA
encoding various PLC constructs as indicated. Pipette solution contained 0.05 mM EGTA and no
added Ca2+. a. Whole-cell currents recorded from control and cells transiently expressing PLCδ1
wild type (WT), dominant-negative PLCδ1 mutant E341R/D343R, PLCβ1 WT, or PLCβ2 WT.
DAMGO (1 µM) and CCh (10 µM) were applied as indicated. Note the complete loss of the
current with PLCδ1-E341R/D343R mutant and faster rate of DAMGO-evoked current
development with PLCδ1 WT compared with PLCβ1/ β2. b. Summary of peak currents at -60
mV evoked by DAMGO and with addition of CCh. *** p < 0.001 vs control by t test. c. Summary
of T90 for DAMGO-evoked current at -60 mV, * p < 0.05, ** p < 0.01 vs PLCδ1 WT by t test.
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Figure 29. PLCδ1 is necessary for DAMGO-evoked TRPC4 but not TRPC5 activation
The dominant-negative PLCδ1 mutant (E341R/D343R) suppressed TRPC4α but not TRPC5
currents. HEK293 cells stably co-expressing µOR and TRPC4α or TRPC5 were transiently
transfected with the control vector (pcDNA3.1) or cDNA for PLCδ1-E341R/D343R. Whole-cell
currents were recorded as in Fig. 28. Shown are means ± SEM of peak currents at -60 mV for n
= 6 - 8 cells. ** p < 0.01, *** p < 0.001 vs corresponding controls by unpaired t test.
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PLCδ1 has been shown to be inhibited by RhoA (Hodson, Ashley et al. 1998, Murthy,
Zhou et al. 2004). Indeed, when co-expressed, the constitutively active mutant of RhoA (L63)
strongly inhibited TRPC4β (Fig. 30a, b). By contrast, expression of a dominant-negative RhoA
mutant (N19) or RhoA-suppressing C3 exoenzyme accelerated the rate of TRPC4β activation
without affecting peak amplitude (Fig. 30a, b, c), suggesting that RhoA inhibition of PLCδ1
might underlie the slow kinetics of Gi/o -mediated TRPC4 activation. Importantly, inhibition by
RhoA-L63 was reversed by co-expression of a constitutively active PLCδ1 mutant (δ1-ΔXY)
(Hicks, Jezyk et al. 2008) (Fig. 30a, b), demonstrating PLCδ1 as the specific target of RhoA in
the context of TRPC4 activation. As controls, we verified that the PLCδ1 and RhoA mutants
affected neither TRPC4β surface expression (Fig. 31a), nor CCh-stimulated Ca2+ store release
(Fig. 31b, c), indicating that Gq/11-PLCβ pathway and TRPC4β trafficking remained intact under
these conditions.
To test isoform specificity of PLCδ dependent facilitation, I coexpressed wild-type
PLCδ1, PLCδ3 or PLCδ4 isoforms with and without the dn-PLCδ1 mutant E341R/D343R (Fig.
32). All three isoforms showed unique effects on TRPC4 peak currents and kinetics. While the
peak currents were similar for PLCδ1 and PLCδ3 overexpressing cells, the time-to peak was
dramatically reduced with PLCδ3. Both peak currents and rise-times were suppressed with
overexpression of PLCδ4 (Fig 32a-f). In the presence of coexpressed dn-PLCδ1, overexpression
of WT-PLCδ1 partially rescued DAMGO-evoked currents. Coexpression of PLCδ3, but not
PLCδ4, also partially rescued DAMGO-evoked currents but to a lesser degree than PLCδ1. It is
likely that PLCδ3 can partially mimic the effect of PLCδ1; however the strong inhibition seen
with coexpression of PLCδ4 could either arise from the sequestration of PLCδ4 at the nucleus or
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by PLCδ4 behaving as a dominant negative – sequestering PIP2 at the plasma membrane, but
unable to enzymatically act on TRPC4.
Next, I examined whether, similar to the facilitation provided by PLCβ activation, other
PLC pathways (for example, PLCγ) could also facilitate Gi/o-mediated activation of TRPC4.
Under subthreshold levels of Gi/o activation with 30 nM DAMGO, activation of epidermal growth
factor receptor (EGFR) facilitated TRPC4β activation, where subsequent addition of CCh did not
cause any further increase (Fig. 33a, b). The current, however, was still dependent on the
activation of PLCδ1 because it was abolished by the expression of dn-PLCδ1, emphasizing the
critical role of PLCδ1 in Gi/o-TRPC4 activation. Stimulation of EGFR alone did not activate
TRPC4β (Fig. 31c). However, it appeared to increase the rate of TRPC4β activation by
stimulation of µOR with DAMGO, similar to that by CCh acting via Gq/11-PLC signaling.
Therefore, facilitation of the PLCδ1-dependent, Gi/o-mediated, TRPC4 activation could be a
general property of all PLC isoforms.
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Figure 30. RhoA modulates PLCδ1’s effect on TRPC4 activation
a. Whole-cell currents recorded from control and cells transiently expressing RhoA WT,
dominant-negative RhoA mutant (RhoA-N19), RhoA inhibiting enzyme C3 exoenzyme (C3-exo),
constitutively active RhoA mutant (RhoA-L63), or RhoA-L63 together with constitutively active
PLCδ1 mutant (δ1-ΔXY). RhoA-N19 and C3-exo abolished biphasic current development
induced by DAMGO while RhoA-L63 eliminated TRPC4β current, which was rescued by δ1ΔXY. b & c. Summary of peak currents at -60 mV evoked by DAMGO and with addition of CCh
(b) and T90 for DAMGO-evoked current at -60 mV (c). *** p < 0.001 vs control and ## p < 0.01
vs RhoA-L63 alone in b and * p <0.05 vs control in c, by t-test.
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Figure 31. TRPC4 surface expression and store release is unmodified by PLCδ1 regulation
a. Cell surface expression of TRPC4β determined by surface biotinylation. TRPC4 in biotinylated
(surface) fractions and in total proteins was determined by Western blotting. Actin was used as
loading control. Transfection efficiency was ~80% as evaluated by GFP. The expression of
indicated proteins in the stable cell line did not alter surface and total expression levels of
TRPC4β. b & c. Overexpression of PLCδ1 (b) and RhoA (c) mutants did not affect Gq/11-PLCβ
activation, as revealed by CCh-evoked store Ca2+ release. Stable HEK293 cells co-expressing
µOR and TRPC4β were transiently transfected with pEGFP-N1 plus the control vector
(pcDNA3.1) or the indicated cDNA constructs, seeded on glass coverslips and loaded with Fura2. Cells were imaged in a Ca2+-free external solution (with 0.2 mM EGTA) for fluorescence ratio
changes when excited alternately at 340 and 380 nm and challenged with CCh (30 µM). Shown
are integrated fluorescence ratio (F340/380) changed elicited by CCh for individual cells over a
60-sec period (area under the curve). The blue boxes and bars show means ± S.E.M. for n = 3
coverslips each with 10 - 30 cells per condition.
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Figure 32. PLCδ isoforms have unique effects on Gi/o-mediated TRPC4 activation and
reversal of dn-PLCδ1-induced inhibition
a-d. Representative whole-cell current traces (upper) and I-V curves (lower) recorded from stable
µOR and TRPC4β co-expressing cells transiently transfected with an empty vector (a), human
PLCδ1 (b), PLCδ3 (c), PLCδ4 (d). Recording conditions are as in Fig. 28. e & f. Summary of
peak currents evoked by DAMGO and with addition of CCh (e) and T90 for DAMGO-evoked
current at -60 mV (f). g. Similar experiments as in a-e, but cells were also transiently expressed
dn-PLCδ1 mutant (E341R/D343R) where indicated. Summary of peak currents at -60 mV evoked
by DAMGO and with addition of CCh are shown as means ± SEM. The number of cells are shown
in parentheses.
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Figure 33. PLCγ facilitates Gi/o-mediated TRPC4 activation in a PLCδ1-dependent manner
All cells stably co-expressed TRPC4β and µOR. Whole-cell currents were recorded with the
pipette solution containing 0.05 mM EGTA with no added Ca2+. Cells were starved for 4 hours
before experiments, by incubation in ECS at 37 °C to prevent EGFR desensitization induced by
factors present in the culture medium. During experiments 50 ng/mL EGF was added after
solubilization in ECS and applied via gravity driven perfusion as indicated. a. Below threshold
activation by DAMGO (30 nM) was facilitated by EGF (upper panel) but was suppressed by
overexpression of the dn-PLCδ1 mutant (lower panel). b. Summary data (means ± S.E.M.) of
peak current at -60 mV for (a), n = 6 cells. * p < 0.05 by paired t-test. c. Treatment with EGF
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alone did not result in TRPC4-like currents but accelerated the rate of DAMGO (1 µM)-evoked
currents.
Summary V: PLCδ1 is a component downstream to intracellular Ca2+ elevation
that is necessary for Gi/o mediated TRPC4 activation. The activation of other PLC
isoforms – PLCβ and PLCγ likely facilitates the action of PLCδ1 on TRPC4
through the increase of intracellular Ca2+.

3.3 Discussion
Although TRPC channels are commonly thought as receptor-operated channels gated by
PLC signaling, I show here that the Gq/11-PLCβ pathway may not be essential for TRPC4
activation. Rather, the channel requires Gi/o proteins for activation and exhibits an unexpected
dependence on PLCδ1, making it a coincidence detector of Gi/o and PLCδ1 signaling. PIP2 is both
a substrate and a membrane docking site of PLCδ1 while Ca2+ is the main activator (Cifuentes,
Honkanen et al. 1993, Essen, Perisic et al. 1996). Also, PLCδ1 is directly inhibited by the small
GTPase, RhoA (Hodson, Ashley et al. 1998). Therefore, PLCδ1 appears to be central for the PIP2
and Ca2+ dependence of TRPC4 activation. By inhibiting PLCδ1, endogenous RhoA likely
contributes to the biphasic kinetics of Gi/o-activated TRPC4 current. Thus, disrupting RhoA
function can accelerate channel activation. The specific effect of RhoA on PLCδ1 was confirmed
by the finding that inhibitory effect of constitutively active RhoA mutant on TRPC4 activation
was reversed by the constitutively active mutant of PLCδ1. Intriguingly, inhibiting PLCδ1 with
either the active RhoA mutant or a dominant-negative PLCδ1, or reducing PLCδ1 expression by
siRNA-mediated knockdown, abolished the effect of not only Gi/o, but also that of Gi/o and Gq/11
co-stimulation, implicating a unique role of PLCδ1 that cannot be substituted by Gq/11-PLCβ.
Thus, other than PIP2 hydrolysis, there may be more intimate coupling and/or interaction between
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PLCδ1 and TRPC4. The lack of effect of PLCδ1 inhibition on TRPC5 activation further argues
for the coupling specificity.
Although PIP2 has been reported to have both positive and negative effects on TRPC
channels (Lemonnier, Trebak et al. 2008, Otsuguro, Tang et al. 2008, Trebak, Lemonnier et al.
2009, Kim, Jeon et al. 2013), the mechanism of its action remains mysterious. Studies with DAGsensitive TRPC3/C6/C7 channels have revealed a strong dependence on PIP2 itself to maintain
channel activity, in addition to serving as a substrate for DAG production (Imai, Itsuki et al. 2012,
Itsuki, Imai et al. 2012, Itsuki, Imai et al. 2014). Similarly, increasing PIP2 levels attenuated
desensitization of TRPC4β and TRPC5 (Kim, Kim et al. 2008, Kim, Jeon et al. 2013). Since
PLCδ1 plays an essential role in TRPC4 activation, the substrate dependence may be explained
by the fact that membrane translocation of PLCδ1 requires PIP2 (Cifuentes, Honkanen et al. 1993).
However, this may not be applicable to other TRPCs, including the closely related TRPC5, which
is not dependent on PLCδ1.
PIP2 may also exert its action by physically interacting with TRPC4 channel complex.
Although it was shown that PIP2 bound to the C-terminal region present in TRPC4α but not in
TRPC4β (Otsuguro, Tang et al. 2008), it may also interact with TRPC4/C5 in a Ca2+-dependent
manner through SESTD1, a protein that binds to the CIRB site (Miehe, Bieberstein et al. 2010).
However, both modes of interactions have been linked to channel inhibition. I show here that
dephosphorylating PIP2 facilitated TRPC4β activation, indicating the presence of a tonic
inhibition by PIP2 on not only TRPC4α but also TRPC4β. Combining previous results, our data
suggest two forms of PIP2 inhibition on TRPC4: one unique to TRPC4α and another common to
both, since α incorporates the entire sequence of the β isoform (Otsuguro, Tang et al. 2008). In
the previous study, the TRPC4α specific inhibition was uncovered with Gi/o and Gq/11 co81

stimulation when the phospholipid content was elevated using exogenous PIP2 (Otsuguro, Tang
et al. 2008). Thus, with [PIP2] elevated, Gq/11-PLCβ stimulation disrupted inhibition of TRPC4β,
but not TRPC4α suggesting a lower affinity PIP2 interaction at the common site than the unique
site, which would be consistent with the conditions used in the current study to reveal PIP2
inhibition on TRPC4β, i.e. weak Gi/o and no Gq/11-PLCβ stimulation. Thus, one way that receptor
stimulation causes TRPC4 activation is to reduce PIP2.
The downstream factor from PIP2 hydrolysis that supports TRPC4 activation appears to
be Ca2+. Since continued [Ca2+]i rise can also be maintained by Ca2+ influx through open TRPC4
channels, the reliance on PIP2 to produce a Ca2+ signal could be extraneous except for generating
an initial trigger. As micromolar [Ca2+]i is needed for TRPC4 activation and the channel is also
inhibited by slightly higher [Ca2+]i, the dynamics of [Ca2+]i change must be critical. With low
EGTA concentrations that allow [Ca2+]i to fluctuate, peak currents were about 2-fold higher than
when [Ca2+]i was clamped to 10 µM by BAPTA, supporting the importance of spatiotemporal
dynamics of Ca2+ in TRPC4 regulation. Yet, Ca2+ alone did not recapitulate the effect of CCh on
activation kinetics, suggesting involvement of additional components of PLC signaling in TRPC4
gating. I did not find any effect of IP3, DAG and PKC on amplitude or kinetics of IM+DAMGOevoked TRPC4β current. Rather, my data suggest that the rate-limiting step is PLCδ1 activation,
on which both Ca2+ and PIP2 may converge to control channel gating. PIP2 hydrolysis and Ca2+
signals generated from PLCδ1 activity could further enhance channel opening. Altogether, the
PLCδ1-TRPC4 duet forms a self-reinforcing loop for continued channel activation in a Ca2+- and
PIP2-dependent fashion. The system requires Gi/o activation, with Gq/11-PLCβ (or other PLC, such
as PLC) acting as an accelerator and RhoA as a brake (Fig. 34).
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Figure 34. Model of the PLCδ1-TRPC4 self-reinforcing system
Positive and negative effects necessary for TRPC4 activation are indicated in green and red lines,
respectively. Non-essential, modulatory effects are indicated in black. In addition to activating
PLCδ1, Ca2+ might directly enhance channel function, based on previous work with TRPC5.
Therefore, at least 3 self-reinforcing loops exist to sustain TRPC4 activity in the presence of Gi/o
stimulation: positive feedback between Ca2+ and TRPC4 (1), PLCδ1, Ca2+ and TRPC4 (2), a
double negative effect between PLCδ1, PIP2 and TRPC4 which is continuously supported by Ca2+
that links TRPC4 function to PLCδ1 activation (Chatzigeorgiou, Yoo et al. 2010). The system is
facilitated by Gq/11-PLCβ pathway which provides the Ca2+ signal for PLCδ1 activation and helps
lower the barrier of channel gating by reducing PIP2. It is negatively regulated by RhoA through
inhibiting PLCδ1 and high Ca2+ levels, which may inhibit either TRPC4 or PLCδ1, or both
(dashed lines).
Because of the dual regulation by both Ca2+ and PIP2, the system should also be very
sensitive to signaling processes that alter the levels of these intracellular messengers, making
TRPC4 a versatile sensor and integrator of diverse transmitter inputs, critical for its functions in
neurons and muscles. Interestingly, persistent TRPC4 activation was observed in lateral septal
neurons exposed very briefly to an mGluR agonist in a manner dependent on [Ca2+]i changes and
voltage-gated Ca2+ channel activation (Tian, Thakur et al. 2013), adding another variable in native
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cells where membrane depolarization and Ca2+ entry via voltage-gated channels can be critical
for TRPC4 function. Moreover, interplay among Gi/o, PLCδ1, and Ca2+ entry channels has been
documented in rabbit gastric smooth muscle where activation of Gi/o -coupled receptors caused
delayed activation of PLCδ1 in a manner thought to depend on SOCE and inhibited by RhoA
(Murthy, Zhou et al. 2004). However, the pharmacology used and presence of TRPC4 in these
cells (Lee, Jun et al. 2005) would argue that the entry channel was formed by TRPC4. Therefore,
not only does PLCδ1 support TRPC4 activation, but also TRPC4 function enhances PLCδ1
activity. The positive feedback loops formed by this system should have strong implications to its
function as an environmental and stress sensor in the gastrointestinal (GI) tract (Tsvilovskyy,
Zholos et al. 2009), cardio-pulmonary vasculature (Tiruppathi, Freichel et al. 2002, Tiruppathi,
Minshall et al. 2002), and neurons (Munsch, Freichel et al. 2003, Phelan, Mock et al. 2012).
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Chapter 4
Calmodulin has a dual action on TRPC4β activity
4.1 Introduction
In the previous chapter, I demonstrated that Gi/o-medicated TRPC4 activation was bidirectionally regulated by intracellular Ca2+. Although the Ca2+-dependence of PLCδ1 may
explain, to a large extent, the Ca2+ requirement that supports the reinforcing positive feedback
loop between PLCδ1 and TRPC4, there remains a possibility that other Ca2+ targets also
participate in the regulation of channel function. CaM can bind to TRPC4α at four sites (one at
the N terminus and three at the C terminus) and TRPC4β at two sites (one at the N terminus and
one at the C terminus). The common site at the C-terminus is the CIRB domain, which is
conserved in all TRPC isoforms and interacts with CaM in a Ca2+-dependent manner (Tang, Lin
et al. 2001, Zhu 2005). In the presence of Ca2+, the interaction between IP3R and TRPC is inhibited
by CaM. Additionally, it had been shown that in inside-out patches TRPC4-like activity was
facilitated in the presence of the CaM inhibitor, calmidazolium. However, it remains unclear
whether CaM inhibits only TRPC4 function, or if it has other effects on the channels, and to what
extent the CIRB domain contributes to these effects. Here, I tested the hypothesis that a part of
the Ca2+ dependent facilitation and/or inhibition of TRPC4 activation may arise from the
regulation of TRPC4 by Ca2+-CaM.
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4.2 Results
4.2.1 Pharmacological inhibition of CaM modulates TRPC4 currents bimodally
Pharmacological inhibition of endogenous CaM in HEK293 cells using ophiobolin A
(Oph-A) or calmidazolium (CMZ) perfused through the patch pipette resulted in a facilitation of
the Gi/o -mediated TRPC4β response activated by a weak stimulation of µOR (with 30 nM
DAMGO) (Fig. 35). This suggested that CaM has an inhibitory effect on the activation of TRPC4.
In contrast, when high doses of DAMGO and CCh were used to maximally activate the channel,
the CaM inhibitors resulted in a partial inhibition of the peak TRPC4 current. This result suggested
that either Ca2+-CaM contributes towards full activation of TRPC4 or that CaM inhibitors have a
non-specific effect that reduces the peak TRPC4 response.

4.2.2 Disruption of CaM binding to TRPC4β C terminus facilitates channel activation
To identify the site of action of CaM as well as to eliminate the possibility that the effects
on TRPC4 were a result of non-specific reactions of CaM inhibitors, I used a TRPC4β mutant
where the CIRB domain has been modified so that IP3R binding is allowed at the domain but the
binding of CaM is not (based on X-ray crystallographic data on CaM-TRPC5 interactions from
Dr. Jian Yang’s lab, Columbia University). The mutated channel protein is referred to as TRPC4βIRB mutant (or IRB).
Compared to the wild type channel, the IRB mutant was activated more strongly at low
concentrations of DAMGO, but showed reduced peak currents in response to the co-stimulation
of both Gi/o and Gq/11 pathways by DAMGO and CCh (Fig 36), mirroring the dual regulation seen
with pharmacological inhibition of CaM. These two sets of experiments suggest that it is indeed
the action of CaM on the TRPC4 CIRB domain that regulates channel activity. Interestingly, the
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N terminal CaM binding (NCB) site mutant (ΔNCB) which had the binding site deleted, showed
a complete ablation of current. At this moment it is not known whether this mutant: 1) renders the
channel silent, or 2) prevents channel subunits from assembling into functional tetramers or 3)
prevents trafficking of the channel to the plasma membrane.
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Figure 35. OphA and CMZ modulate TRPC4 currents bimodally
All cells stably co-expressed TRPC4β and µOR. a-c. In the whole-cell patch clamp configuration,
CaM inhibitor, Oph-A (a,b) or CMZ (c) (each 10 µM) was infused into the cell through the patch
pipette and allowed to dialyze into the cell for 5 minutes. Cells were subsequently stimulated with
30 nM DAMGO. Both CaM inhibitors facilitated TRPC4 activation under application of
subthreshold concentrations of DAMGO. d-f, Similar to a-c, but maximal stimulation of TRPC4
by co-activation of Gi/o and Gq/11 was carried out with 1 µM DAMGO and 30 µM CCh. In this
case, the CaM inhibitors suppressed the peak TRPC4 currents. For controls, appropriate amounts
of DMSO (solvent used for both Oph-A and CMZ) were added to the patch pipette solution.
Summary data (means ± SEM) for DAMGO or DAMGO + CCh-evoked peak currents at -60 mV
are shown. Concentration of EGTA in all patch pipette solutions was 0.05 mM with no added
Ca2+.
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Figure 36. Disruption of CaM binding to TRPC4 CIRB domain facilitates channel activation
by weak Gi/o stimulation but inhibits the peak currents evoked by strong co-stimulation of
both Gi/o and Gq/11 pathways
a & b. In cells stably expressing µOR and transiently expressing the TRPC4β C-terminal CaM
binding site mutant ‘IRB’, a subthreshold concentration of DAMGO (30 nM) showed similar
levels of activation in the absence and presence of Oph-A. In comparison with cells transiently
expressing wild type TRPC4β, the IRB mutant showed higher peak currents in response to 30 nM
DAMGO. Note, cells transiently expressing TRPC4β showed weak response to 30 nM DAMGO,
unlike the lack of response seen in cells stably expressing this channel under the same conditions
(Fig 35). This might be due to the higher expression levels with transient transfection. Similar to
figure 35d-f, under maximal stimulation by DAMGO and CCh, the IRB mutant showed
suppressed peak currents in comparison with cells transiently expressing the wild type channel.
Summary data (means ± SEM) for DAMGO or DAMGO + CCh-evoked peak currents at -60 mV
are shown. Concentration of EGTA in all patch pipette solutions was 0.05 mM with no added
Ca2+.
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4.2.3. Ca2+ binding defect mutants of CaM alter TRPC4 response to Gi/o stimulation
Next, I examined whether a modification of the Ca2+ binding sites of CaM would alter the
response of TRPC4 to Gi/o and/or Gq/11 stimulation, based on the previous finding that certain
CaM mutations selectively impair its association with the TRPC4 C terminal CIRB domain (Zhu
2005). Of these, the EF3 mutant, where a single amino acid substitution (Glu104 to Ala) renders
it ineffective to bind to Ca2+ at this site, was shown to be least affected for binding to TRPC4
CIRB domain in comparison with other CaM mutants, such as Glu31Ala (EF1), Glu67Ala (EF2),
or Glu140Ala (EF4) or double mutants EF1,2 and EF3,4. Similarly, although the CIRB domains
of TRPC1 and TRPC5 (but not TRPC2, 3, 6) also showed high affinities to the EF3 mutant, the
TRPC5 CIRB domain showed even higher affinity to EF4 and EF3,4 mutants (Zhu 2005), which
may account for differential modulation of TRPC4 and TRPC5 by CaM.
In whole-cell recordings, overexpression of the CaM EF3 mutant but not the EF3,4 mutant
led to a facilitation of the TRPC4 current development in response to subthreshold stimulation of
µOR by DAMGO (Fig. 37a). However, there was no significant change in the peak currents in
response to maximal stimulation of Gi/o and Gq/11 signaling (Fig. 37b). The facilitation seen with
the EF3 mutant, but not the EF3,4 mutant, mirrors the difference in binding seen with the TRPC4
CIRB domain, where EF3 binds to the TRPC4 CIRB domain but EF3,4 does not (Zhu 2005). As
the CaM EF3,4 mutant does not bind to TRPC4, its overexpression was not expected to impact
channel function as it would be unable to compete with the endogenous CaM to exert any effect.
On the other hand, the overexpressed EF3 can compete with endogenous CaM and occupy the
binding site, but in a different configuration because of the loss of Ca2+ binding to the 1st EF hand
at the C-lobe. It is well known that CaM C-lobe binds to Ca2+ with high affinity (Linse,
Helmersson et al. 1991) and is most likely Ca2+ bound under resting [Ca2+]i. Therefore, the C-lobe
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binding to TRPC4 may present an inhibitory action on channel opening, which was crippled by
disrupting Ca2+ binding to CaM EF3, in the TRPC4β-IRB mutant or by treatment with CaM
antagonist. On the other hand, the N-lobe of CaM, which binds to Ca2+ with low affinity, may be
involved in enhancing TRPC4 function. Because this interaction requires high [Ca2+]i, it is more
apparent when the channels are strongly activated. This interaction was not disrupted by the
mutation at EF3 of CaM, but abolished by the TRPC4-IRB mutant or treatment with CaM
antagonist. Therefore, the decrease in TRPC4 peak currents in response to maximal stimulation
was only detected under the two later conditions, but not when CaM EF3 mutant was
overexpressed. These results indicate that CaM regulates channel activity through binding to the
C-terminal CIRB site where binding conformations change in response to elevation of [Ca2+]i,
such that at low resting [Ca2+]i, CaM C-lope binding inhibits channel opening whereas upon
[Ca2+]i rise, the N-lobe binding facilitates channel opening. This dynamic change in CaM
conformation explains the bimodal effects of CaM on TRPC4 channel function.

Summary VI: CaM regulates Gi/o mediated TRPC4 activation. At low resting [Ca2+]i
(likely Ca2+ bound at the C-loop), CaM posts an inhibition on TRPC4 activation. At
high [Ca2+]i (likely Ca2+bound at both N- and C-loops), CaM facilitates TRPC4
activation. The dual effects of CaM was revealed by the use of CaM antagonists and
the CIRB domain mutant of TRPC4β for which CaM binding to its C terminus is
prevented.

90

a

b
4
Peak current (-nA)

Peak current (-nA)

1.5

*
1.0

9

0.5
8

CaM:

CTRL

9
2

6

6
8

1
6
6

0.0

3

WT

EF3

0

CaM:

EF3,4

30 nM DAMGO

CTRL

WT

EF3

EF3,4

1 µM DAMGO+30 µM CCh

Figure 37. CaM mutants have differential effects on TRPC4
All cells stably co-expressed TRPC4β and µOR. Wild type CaM or CaM mutants in pcDNA3.1
were transiently transfected and cells were recorded by whole-cell patch clamping after 16-24
hours. Summary data (means ± SEM) for DAMGO or DAMGO + CCh-evoked peak currents at
-60 mV are shown. Concentration of EGTA in all patch pipette solutions was 0.05 mM with no
added Ca2+.

4.3. Discussion
Although Ca2+-CaM binding to TRPCs have been demonstrated long before (Zhu 2005),
exactly how such interactions affect the channel function remains largely unexplored. TRPC4 is
particularly complex with respect to CaM regulation because of the presence of multiple CaMbinding sites. Therefore, I decided to focus on TRPC4 as it contains two less CaM-binding sites
than TRPC4 and therefore allows a better opportunity of dissecting the site-specific regulation.
In addition, the availability of crystallographic structure of Ca2+-CaM-bound TRPC5 CIRB
domain makes it possible to predict the critical residues in TRPC4 CIRB domain involved in
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coordinating the interaction with CaM, allowing specific disruption of CaM binding to this
domain with minimal unintended effect on other regulatory functions. Intriguingly, the CIRB
mutant appears to be responsible for both the tonic inhibition on channel activation by Gi/o
signaling and the potentiation of channel function in response to strong stimulation. That both of
these effects are mediated by CaM, was demonstrated by the observation that pharmacological
inhibition of CaM had almost identical consequences as disrupting CaM binding to the TRPC4
CIRB domain. Furthermore, the dual effects of CaM can most likely be explained by C-lobe
binding to the CIRB site under resting [Ca2+]i, while the elevation of which due to the TRPC4
channel function itself and/or other [Ca2+]i rising mechanisms recruit the N-lobe to alter CaM
interaction at this critical motif to enhance channel function. This novel mechanism of Ca2+-CaM
regulation on TRPC4 warrants additional investigation.
Unlike the CIRB site, little is known about how CaM binds to the N-terminal CaM binding
(NCB) site of TRPC4. Since no crystal structure is available for this domain, it has been difficult
to design strategies to selectively disrupt CaM binding at the NCB site. So far, all attempts
targeting the NCB domain have rendered TRPC4 non-functional. Therefore, the NCB site
appears to be critical for channel function and/or assembly and/or trafficking. It would require
additional work to sort out these possibilities. One of the additional CaM-binding sites of TRPC4α
has a very low affinity for Ca2+ (~600 nM) compared to the CIRB domains of all TRPCs (Tang,
Lin et al. 2001). This site therefore might function as a negative regulatory site in the presence of
high [Ca2+]i. However, since Ca2+-dependent inhibition was also observed in TRPC4, the Ca2+
dependent inhibition shown in Fig. 24d has to be intrinsic to both TRPC4 and C4, arguing for
a more finite regulation by the extra CaM-binding site in TRPC4α. Further experimentation and
possibly molecular dynamics simulations with a TRPC4C terminus co-crystallized with CaM or
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a homology based structure prediction based on the crystallized TRPC5 C terminus, should shed
more light on the multimodal regulation of CaM on TRPC4.
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Chapter 5
Protons accelerate Gi/o -mediated TRPC4 activation in a Ca2+-dependent manner
5.1 Introduction
In Chapter 3, I have shown that [Ca2+]i rise enhanced the probability, but not the rate, of
whole-cell current development of TRPC4β in response to stimulation of Gi/o proteins via µOR
activation, indicating that the Ca2+ signal alone cannot completely recapitulate the effect of Gq/11PLCβ stimulation via endogenous muscarinic receptors. Considering the factors of the PLC
pathway that may cooperate with Ca2+ to facilitate TRPC4 activation, I had examined various
products or downstream signals of PIP2 hydrolysis, including DAG, PKC, and IP3, but did not
observe any obvious effect (See Ch. 3). There is one more, but often overlooked, PIP2 hydrolysis
product H+, which is generated at a molar ratio of 0.8 per substrate and was shown to be critical
for activation of TRP and TRPL channels in Drosophila photoreceptors (Huang, Liu et al. 2010).
Protons regulate the latency of Drosophila TRP channel in response to repeated light
stimuli via their effect on the scaffolding protein INAD, which contains five postsynaptic
density/discs-large/zonula occludens (PDZ) domains and coordinates the formation of a complex
composed of TRP, rhodopsin and PKC. Although an ortholog of INAD does not exist in
mammals, another scaffolding protein called NHERF (Na+/H+-exchanger regulatory factor)
consisting of two PDZ domains has been shown to be associated with TRPC4 and PLCβ (Tang,
Tang et al. 2000). This raises the possibility that TRPC4 may also be modulated by intracellular
protons in a similar fashion as Drosophila TRP channels.
Supporting the modulatory effect of protons on TRPC4 function, the activities of TRPC4
and the closely related TRPC5 were shown to be facilitated by an acidification of the extracellular
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solution (Semtner, Schaefer et al. 2007). A mutation of Glu543 located in the P-loop to Gln only
eliminated pH potentiation of GTPγS-evoked current but did not completely abolish the pH
potentiation of basal TRPC5 current, suggesting the presence of an additional proton sensor(s).
As extracellular acidification induces intracellular acidification in HEK293 cells, it is likely that
the pH potentiation of TRPC5 and therefore also TRPC4 may occur from the intracellular side.
Therefore, I examined whether and how intracellular acidification could affect TRPC4 activation.
I focused especially on activation kinetics because this property was unaffected by increasing
[Ca2+]i in the absence of Gq/11-PLCβ stimulation.

5.2 Results
Again, the stable HEK293 cell line co-expressing TRPC4β and µOR was used for wholecell voltage clamp recordings. Pipette solutions contained 0.05 mM EGTA and no added Ca2+ to
allow TRPC4 activation by co-stimulation with DAMGO and IM (both at 1 µM). I used three
methods to lower intracellular pH (pHi). First, pHi was clamped by a higher HEPES concentration
(50 mM) to either 6.5 or 7.2 in the pipette solution. Similar to the standard pipette solution as
shown in Figs. 23a and 26a, in the presence of IM, DAMGO evoked a biphasic current
development with pHi clamped to 7.2. However, with pHi clamped to 6.5, the biphasic current
development was eliminated, resulting in a faster activation kinetics than the pH 7.2 pipette
solution without a change in the peak current (Fig. 38a-c).
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Figure 38. Protons accelerate Gi/o -mediated TRPC4 activation
For a-c, all cells stably co-expressed TRPC4β and µOR and pipette solutions contained 0.05 mM
EGTA with no added Ca2+. a, Whole-cell currents evoked by DAMGO (1 µM) in the presence of
IM (1 µM) in cells dialyzed with pipette solutions having pH buffered to 7.2 (upper panel) and
6.5 (lower panel) by 50 mM HEPES. Note the faster development of current with pHi of 6.5. b &
c, Summary (means ± SEM) of peak currents (b) and T90 (c) at -60 mV evoked by DAMGO in
the presence of IM. n = 7 for each. * p ≤ 0.05 by unpaired t test.
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However, intracellular dialysis does not allow changing pHi at desired time points and the
low pH solution could potentially elicit undesired currents upon making whole-cell - thereby
interfering with Gi/o-mediated TRPC4 currents. Therefore, I used the sodium acetate (NaAc)
gradient method (Yuan, Shimura et al. 2003, Niemeyer, Cid et al. 2010) to alter pHi through bath
perfusion while maintaining a constant extracellular pH (pHo = 7.4). To do this, 5 mM NaAc was
included in the pipette solution adjusted to pH 7.4. With the cell held under whole-cell
configuration, increasing extracellular NaAc concentration to 7.9, 39.5, or 125.4 mM (with equal
molar exchange for NaCl, all at pH 7.4) led to the expected pHi drop to 7.2, 6.5, or 6.0 according
to the formula given in Chapter 2, page 56. These pHi changes were confirmed by imaging
fluorescence ratio changes inside the cell with BCECF under the exactly the same conditions used
for whole-cell recordings (Fig. 40a). With co-stimulation by IM (1 µM), I showed that reducing
pHi to 7.0 markedly decreased T90 of DAMGO-evoked TRPC4β current by ~9 s (Fig. 39c).
Maximal decreases (final T90 ranged from 4.4 to 6.1 sec, n = 16) were obtained in the pHi range
of 6.25 to 6.75 (Fig. 39a,c). However, T90 became much longer at pHi < 6.25, indicating that,
mirroring the effect of Ca2+, the pH regulation is also bi-directional, with pHi 7 to 6.25 being
facilitating and pHi < 6.25 being inhibitory. Fitting the data points with a biphasic Hill equation
yielded the pHi of 7.25 for half maximal facilitation and pHi of 6.09 for half maximal inhibition for proton effects on the rate of TRPC4 activation (Fig. 39c). Remarkably, [Ca2+]i rise was needed
for the proton effects as in the absence of IM, T90 remained about constant across the entire pH
range tested (Fig. 39c). Furthermore, the maximal current amplitudes were unchanged by pHi or
IM (Fig. 39b). Therefore, intracellular pH strongly affected the kinetics of Gi/o-mediated TRPC4β
activation when [Ca2+]i was elevated. While TRPC4α was similarly regulated by pHi as TRPC4β,
TRPC5 only showed facilitation but not inhibition by pHi, at least until pH 6.0 (Fig. 39c).
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Moreover, the facilitation effect by pHi 6.5 on T90 was also detected with free [Ca2+]i clamped to
10 µM by 10 mM BAPTA without IM stimulation (Fig. 40b), confirming it is Ca2+, rather than
IM, dependent.
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Figure 39. Protons accelerate Gi/o -mediated TRPC4 activation in a Ca2+-dependent manner
a. Whole-cell TRPC4β currents evoked by DAMGO (1 µM) following the change of pHi to
varying levels by extracellular application of different concentrations of NaAc as indicated. IM
(1 µM) was applied to increase [Ca2+]i. The pipette solution contained 5 mM NaAc and was
adjusted to pH 7.4. Note the differences in the kinetics of current development with different pHi.
b, Summary (means ± SEM) of peak currents at -60 mV evoked by DAMGO in the presence
(black) and absence (gray) of IM with pHi changed by NaAc to values as indicated. c, Summary
(means ± SEM) of T90 for DAMGO-evoked currents in the presence (circles) and absence
(squares) of IM with pHi changed by NaAc for cells that stably expressed µOR together with
TRPC4β, TRPC4α, or TRPC5 (n = 6-9). Note the lack of inhibition by pH 6.0 for TRPC5. Data
for TRPC4β in the presence of IM were fitted with the biphasic Hill equation assuming maximal
and minimal T90 values of 50 and 3.3 sec. The estimated EC50 for pHi facilitation was 7.25, Hill
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2.15; the estimated IC50 for pHi inhibition was 6.09, Hill -7.07. Data for TRPC4β in the absence
of IM were fitted with linear regression. * p ≤ 0.05 for +IM vs –IM for TRPC4β, ** p ≤ 0.01, ***
p ≤ 0.001 vs TRPC5 (+IM), by unpaired t test.
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Figure 40. Calibration of intracellular pH (pHi) changes induced by NaAc gradients
a, Cells stably expressing TRPC4β and µOR were voltage-clamped at -60 mV with the pipette
solution that contained (in mM): 140 CsCl, 5 NaAc, 1 MgCl2, 0.05 EGTA, and 10 HEPES, pH
7.4, supplemented with 300 µM BCECF (2',7'-Bis-(2-Carboxyethyl)-5-(and-6)Carboxyfluorescein; free K+ salt). The initial bath solution contained (in mM): 140 NaCl, 5 KCl,
2 CaCl2, 1 MgCl2, 10 glucose, and 10 HEPES, pH 7.4. After establishment of the whole-cell
configuration and dialysis for > 5 min, the bath was changed to a solution in which an equal molar
NaCl was replaced with 7.9, 39.5, or 125.4 mM NaAc (all at pH 7.4) with the expected pHi drop
to 7.2, 6.5, or 6.0 while BCECF fluorescence images were taken at alternating excitations of 440
and 490 nm at 3 sec intervals. At the end of the experiment, the cells were exposed to calibration
solutions containing 145 KCl, 2 CaCl2, 1 MgCl2, 10 glucose, and 10 HEPES, supplemented with
10 µM nigericin, with pH adjusted to 7.2, 6.5, and 6.0, and BCECF fluorescence images
continuously taken. Background fluorescence intensities were determined using neighboring cells
not loaded with BCECF. Background subtracted F490/440 ratios from KCl/nigericin calibration
(means ± SEM, n = 5 for each pH) were used to generate the standard curve by linear regression
fit. pHi levels (means ± SEM) for NaAc gradients (n = 5 for each condition) were determined
from the standard curve and were found to be very close to the predicted values. The blue box
represents the BCECF ratio and the calculated pHi in response to the bath application of the pH
6.8 extracellular solution as used in Fig. 41 (n = 4). b, T90 of TRPC4 currents evoked by DAMGO
(1 µM) when free [Ca2+]i was clamped to 10 µM by 10 mM BAPTA and pHi clamped to 7.2 or
6.5 by the NaAc gradient. pHi 6.5 still accelerated the current development under these conditions
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indicating that intracellular Ca2+ rise rather than IM treatment per se was involved in cooperating
with protons to facilitate TRPC4 activation. n = 9, * p < 0.05 by unpaired t test.
Third, because extracellular acidification also reduces pHi (Kettenmann and Schlue 1988),
I tested the effect of lowering pHo on DAMGO-induced TRPC4β activation in the presence of
IM. Changing pHo from 7.4 to 6.8 significantly reduced T90 (Fig. 41a, c). However, since TRPC4
and C5 activities are enhanced by extracellular protons (Semtner, Schaefer et al, 2007), the effect
of pHo 6.8 could reflect regulation at the extracellular side. To prevent the extracellular effect, I
mutated the two critical glutamates, E542 and E543, to glutamines and tested the activation by
DAMGO and IM in cells that co-expressed µOR and TRPC4β (E542Q/E543Q). Again, pHo 6.8
significantly decreased T90 as compared to pHo 7.4 (Fig. 41b, c). Moreover, using a pHi 8.5 pipette
solution to counteract the pHi lowering effect of pHo, I completely prevented the facilitation by
pHo 6.8 on the mutant channel (Fig. 41b, c). For the wild type channel, the pHi 8.5 solution also
partially reversed the facilitation by pHo 6.8 (Fig. 41a, c). Importantly, these manipulations on
pHo and pHi did not significantly change the peak current (Fig. 41d). These results suggest that
extracellular protons potentiated TRPC4 activation through both extracellular and intracellular
mechanisms.
The above results, thus, suggest that protons are another constituent of PLC activation that
cooperates with Ca2+ to support Gi/o-mediated TRPC4 activation. Then preventing the pHi drop
to < 7.0 during co-stimulation of Gi/o and Gq/11 would be expected to slow down channel
activation. Buffering pHi to 8.5 in the pipette solution indeed increased T90 of TRPC4β current
evoked by co-application of DAMGO (1 µM) and CCh (30 µM) and this effect was more
pronounced with the stronger pH buffer by 100 mM HEPES than by the standard 10 mM HEPES
(Fig. 42a, b). Again, the peak current was not changed by the alkaline pHi (Fig. 42c).
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Furthermore, with the optimal pHi and [Ca2+]i, DrVSP-induced current suppression was
significantly decreased (Fig. 43), suggesting a reduced dependence on PIP2 and its products.
Altogether, these results suggest that a moderate pHi decrease due to hydrolysis of PIP2 is a key
component of PLC activation that facilitates Gi/o -mediated TRPC4β activation.
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Figure 41. Extracellular acidification accelerates the rate of Gi/o-mediated activation of
TRPC4β and its E542Q/E543Q mutant, and the effect was blocked by intracellular
alkalinization
a-d, HEK293 cells stably expressing µOR were transiently transfected with cDNA for wild type
(WT) or the E542Q/E543Q mutant of mouse TRPC4β as indicated. Pipette solutions contained
0.05 mM EGTA and no added Ca2+ and the pH was buffered at 7.2 or 8.5 with 100 mM HEPES.
In the presence of IM (1 µM), whole-cell current development in response to DAMGO (1 µM)
was accelerated by lowering extracellular pH (pHo) from 7.4 to 6.8 for both WT (a) and the mutant
(b) TRPC4β channels when pHi was buffered at 7.2 (left panels). However, raising the pHi to 8.5
prevented the accelerating effect of pHo 6.8 (right panels). Summaries (means ± SEM) show
similar facilitation on T90 by pHo 6.8 as CCh (10 µM), but the effect was reversed by pHi 8.5 for
both WT and the mutant channels (c). However, the peak currents at -60 mV were not affected
(d). ** p ≤ 0.01, *** p ≤ 0.001 by unpaired t test.
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Figure 42. Alkaline intracellular pH slows down TRPC4 activation
a. Whole-cell currents evoked by simultaneous application of DAMGO (1 µM) and CCh (10 µM)
in cells that stably co-expressed TRPC4β and µOR. Pipette solutions contained 0.05 mM EGTA
and no added Ca2+ and the pH was buffered at 7.2 or 8.5 with either 10 or 100 mM HEPES. Shown
are example traces with pHi buffered at 7.2 (left panel) and 8.5 (right panel) by 100 mM HEPES
(c) and summaries (means ± SEM) for T90 (b) and peak currents at -60 mV (c) with pHi buffered
at 7.2 or 8.5 with either 10 or 100 mM HEPES as indicated. ** p < 0.01, ns, not significant vs pHi
= 7.2 by unpaired t test. Numbers of cells are shown in parentheses.
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Figure 43. Simultaneous elevations of [Ca2+]i and [H+]i attenuated the PIP2 dependence
Cells that stably co-expressed TRPC4β and µOR were transiently transfected with either
a control vector (a) or the cDNA for DrVSP (b). The pipette solution contained 0.05 mM EGTA
with no added Ca2+ and 5 mM NaAc with the initial pH of 7.4. Cells were held at -60 mV and
currents continuously recorded while a depolarization pulses to 100 mV for 1 sec was applied
every 5 sec. A voltage ramp was added 0.5 sec after each pulse. IM (1 µM) and NaAc (7.9 or 39.5
mM) were applied extracellular to increase [Ca2+]i and clamp pHi to 7.2 (upper panels) or 6.5
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(lower panels) 30 sec before DAMGO (1 µM) was added. The sections indicated by the
arrowheads are expanded at the left. Note the current depression in DrVSP-expressing cells seen
at pHi 7.2 is diminished at pHi 6.5. c, Summary of I/I0. Data are means ± SEM for 4 cells of each
condition.* p ≤ 0.05.
To test whether the proton dependent facilitation required a cystosolic component, I used
excised outside-out and inside-out patches. Because the nominally Ca2+-free solutions made using
the untrapure water from Milli-Q Water Purification system (EMD Millipore) contain very low
Ca2+ (<100 nM by Fura-2 measurement), I assessed the Ca2+- and pH-dependence of TRPC4 using
intracellular solutions made of (in mM): 140 CsCl, 5 KCl, 1 MgCl2, varying CaCl2, and 50 mM
HEPES, with pH adjusted by CsOH to varying levels between 6.0 to 7.2. No Ca2+ chelator was
added to avoid the complex effect of the chelator on pH and free [Ca2+]i. The extracellular solution
was nominally Ca2+ free to avoid [Ca2+]i changes due to Ca2+ influx. In outside-out patches excised
from cells that expressed TRPC4β and µOR, application of DAMGO (1 µM) elicited macroscopic
currents at -60 mV with pHi ranged from 6.4 to 7.4 and [Ca2+]i ranged from 1 to 10 µM (Fig. 44a).
With varying combinations of pHi and [Ca2+]i, I observed an intersecting bimodal dependence,
with maximal currents achieved just below pHi 7.0 at ~ 10 µM Ca2+ (Fig. 44a, b). On the other
hand, only single channel activities were detected in inside-out patches even with the Ca2+
concentration at the cytoplasmic side switched to 10 µM (Fig. 45). Lowering the pHi from 7.2 to
7.0 did not change the activity while lowering it to 6.5 only resulted in inhibition, instead of
facilitation (Fig. 45). This conflict between the outside-out and inside-out patches could be
explained by the difference in the intracellular milieu isolated in the two excised patch techniques
– the outside-out patch is typically a larger portion of the membrane and may retain parts of the
cytoplasm such as the ER and the cytoskeleton. The inside-out patch is expected to contain fewer
cytoplasmic elements. The difference in pHi dependence therefore may arise from a pH sensitive
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cytoplasmic component which is lost in the inside-out configuration. The pH dependent inhibitory
process might be more proximal or directly on the channel. The Ca2+ facilitation might be
accounted for by a direct effect of Ca2+ on the channel domains or on CaM which associates with
the C –terminus (Chapter 4).
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Figure 44. Dependence of macroscopic TRPC4 currents on pHi and [Ca2+]i in outside-out
patches
In HEK293 cells stably expressing µOR and TRPC4β, outside-out recordings were made with
pipette solutions where pH was clamped with 50 mM HEPES and free Ca2+ concentrations set
without any Ca2+ chelator. No Ca2+ chelator or Ca2+ was added to the external buffer, which gave
background levels of nominally free Ca2+ to exist in the solution to allow for only the internal
Ca2+ and pH to influence the currents. a. Representative current traces recorded at – 60 mV
(applied to the intracellular side – inside the patch pipette) at [Ca2+]i of 10 µM and varying pHi as
indicated. Note that DAMGO (1 µM) evoked macroscopic currents. b. Summary of peak currents
(n = 6-8) shows a coincident bimodal dependence – with a narrow range for both pHi and Ca2+i.
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Figure 45. Decreasing pHi inhibits single channel activity of TRPC4 in inside-out patches
In HEK293 cells stably expressing µOR and TRPC4β, inside-out recordings were made with
cytoplasmic solutions where pH was clamped with 50 mM HEPES and free Ca2+ concentration
set without any Ca2+ chelator. DAMGO (10 nM) was added to the patch pipette solution (ECS
described in 2.3). The patches were held at -60 mV (at the intracellular side) and solutions were
applied to the intracellular side by a gravity driven perfusion system. Application of 10 µM free
Ca2+ was sufficient to induce maximal single channel activity which was not further enhanced by
lowering the pHi to 7.0 (upper panel). However lowering pH to 6.5 inhibited the activity
reversibly.
Summary VII: Ca2+ and H+ are two major factors associated with PLC signaling that
act in concert with Gi/o protein activation to gate TRPC4 channels. H+ exerts
bidirectional (facilitation and inhibition) effects on the channel with narrow
concentration ranges, revealing TRPC4 as a finely tuned sensor of coincident Gi/o
stimulation, cytosolic Ca2+ increase and acidification.
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5.3 Discussion

In Chapter 3, I showed an absolute dependence on triggering Ca2+ for Gi/o-mediated
TRPC4 activation. However, in all conditions where [Ca2+]i was increased alone without a
concomitant Gq/11-PLCβ stimulation, it only supported slow development of Gi/o-mediated
TRPC4 whole-cell currents. Here, I show that this delay was abolished by lowering pHi, another
component of PLC signaling not often discussed. Previously, intracellular protons produced
downstream of Gq-PLCβ activation were shown to contribute critically to the activation of related
Drosophila TRP and TRPL channels (Huang, Liu et al. 2010). Therefore, a drop of pHi may be a
common factor involved in PLC-mediated activation of all TRPC channels. The pHi effect also
has a narrow range and is likely local - as shown by the ability of pH 8.5 internal solution to slow
down CCh facilitation when buffered by 100 but not 10 mM HEPES.
The kinetic effect of pHi in whole-cell mode probably reflects the ability of intracellular
protons to lower the Ca2+ threshold of TRPC4 activation. Noticeably, in outside-out patches, both
Ca2+ and H+ only affected peak current amplitude without any obvious effect on activation kinetics
(Fig. 44). The slightly acidic pHi (6.4-6.8) brought down the [Ca2+]i needed to evoke maximal
currents by about 10 fold. To understand how this affects whole-cell current, one has to consider
the fact that TRPC4 proteins are present as clusters on the plasma membrane (Plant and Schaefer
2003, Graziani, Poteser et al. 2010). Presumably, the triggering Ca2+ only randomly opens
channels in a limited number of clusters, which, despite the self-promoting positive feedback
effect within the cluster, is insufficient to display obvious whole-cell currents. Ca2+ diffusion to
neighboring clusters is necessary to generate the global response with robust whole-cell currents.
However, Ca2+ diffusion in the cytosol is limited and heavily influenced by cytosolic Ca2+-binding
proteins and buffers. Thus, the level of Ca2+ that reaches the neighboring clusters may only be
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able to generate a propagating response at low pHi, but not the normal pHi of 7.2. Such a drop in
pHi is normally provided upon stimulation of PLC. In the absence of Gq/11-PLCβ stimulation by
a receptor, other PLC isoforms, e.g. PLCδ, may be recruited by the rising [Ca2+]i to produce the
needed protons. However, this may be another Ca2+ diffusion delimited process that happens
inefficiently until a threshold (most likely the spatiotemporal summation of Ca2+ signals generated
from the influx mediated by the few open TRPC4 channels) is reached. This explains the biphasic
kinetics of TRPC4 activation induced by DAMGO alone or DAMGO plus IM.
Cytosolic Ca2+ increase and acidification are events that typically coincide in the GI
smooth muscle cells and the cardio-pulmonary vasculature during ischemic and hypoxic
conditions (Ladilov, Schäfer et al. 2000) as well as neurons during brain injury and epileptic attack
(Lipton 1999, Pavlov and Walker 2013). A number of studies have shown an upregulation of
TRPC4 in hypoxic conditions (Alzoubi, Almalouf et al. 2013, Parrau, Ebensperger et al. 2013)
and the involvement of TRPC4 in neuronal death (Phelan, Shwe et al. 2013, Nagarajan, Ning et
al. 2014). My results coincide with these findings in suggesting that TRPC4 likely acts as a stress
sensor uniquely sensitive to Gi/o signaling and acidification.

109

Chapter 6
Discussion and future directions

TRPC channels are commonly thought to be gated by PLC signaling, but for TRPC4, Gi/o
proteins are obligatorily involved, making this channel a coincident detector of Gi/o and PLC
signaling. While Gi/oα binding to the C-terminal CIRB domain of TRPC4 protein may be involved
for the Gi/o effect (Jeon, Hong et al, 2012), this action alone is insufficient to maximally activate
the channel. My studies have provided evidence that the TRPC4 activation mechanism consists
of multiple steps:
1) Activation of Gi/o
2) Activation of PLCδ1
3) Increase in intracellular Ca2+
4) Depletion of PIP2
5) Intracellular acidification
Of these steps, 1 – 3 must obligatorily coincide. Inhibition of any one of these three events
completely ablates TRPC4 activity.

6.1 The role of PIP2
The involvement of PIP2 is multifaceted: even though the depletion of PIP2 facilitates the
activation (Chapter 3), the presence of PIP2 is necessary (Fig. 46). One of the most widely used
experimental conditions to strongly deplete PIP2 is the overexpression of the constitutively active
mutant of the Gαq subunit Gqα-Q204L (GqQL). In cells expressing the GqQL mutant, TRPC4
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activity is completely ablated – neither maximal Gi/o, nor coincident Gi/o and Gq/11 activation
produce any TRPC4 current (Fig 46a, top panel). However, overexpression of the constitutively
active PLCδ1 mutant reversed this inhibition suggesting that one of the primary functions of PIP2
in the TRPC4 activation mechanism might be to deliver PLCδ1 to the plasma membrane and
likely into proximity with the channel.
It should be noted that the overexpression of GqQL does not completely deplete PIP2 (Fig.
46c). Sufficient PIP2 remains in the membrane or is re-synthesized constantly by the cell - to allow
for CCh-stimulated Ca2+ store release (Fig. 46c), albeit being smaller than cells that did not
express GqQL. Therefore, it is possible that the constitutively active PLCδ1 mutant needs a
minimal amount of PIP2, which may be supplied by the residual or regenerated PIP2, to translocate
to the membrane and also possibly to perform the function necessary for TRPC4 activation. The
association of PIP2 with the PLCδ1 enzyme in this scenario would then hydrolyze the PLC (or
TRPC4) bound PIP2 and then TRPC4 would be facilitated/activated by a PIP2 hydrolysis product.
However, PIP2 may also act merely as a translocation agent to facilitate a direct coupling of
PLCδ1 or a downstream intermediary with TRPC4. In this scenario the hydrolysis of PIP2 would
not be necessary for the action of PLCδ1 on TRPC4.
The overexpression of the constitutively active mutant of PLCβ2 or the application of the
strongly facilitatory condition of reduced pHi and elevated calcium was insufficient to reverse the
GqQL-PIP2 depletion induced inhibition. To verify whether PLCδ1 needs to interact with the
channel directly or to the membrane to perform its function, co-precipitation assays to examine
physical association between TRPC4 and PLCδ1 could be performed. In addition, membrane
targeting of PLCδ1 by introducing either a myristoyl chain binding motif to PLCδ1 or additional
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PH domains which may exaggerate PLCδ1 targeting to PIP2 rich membrane regions is also
expected to facilitate TRPC4 activation.
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Figure 46. Reversal of PIP2 depletion induced TRPC4 inhibition by constitutively active
PLCδ1
a, Representative whole-cell current traces evoked by DAMGO (1 µM) and DAMGO plus CCh
(10 µM) in cells that stably co-expressed TRPC4β and µOR, and transiently transfected with
human GqQL without or with PLCδ1-ΔXY or PLCβ2-ΔXY as indicated. Pipette solutions
contained 0.05 mM EGTA and no added Ca2+. b, Summary data (means ± SEM) for DAMGO
evoked peak currents at -60 mV are shown. **p < 0.01 vs control by unpaired t test. Numbers of
cells are shown in parentheses. c, Cells stably co-expressing TRPC4β and µOR were transiently
cotransfected with EGFP and human GqQL, trypsinized at 20 hrs post-transfection and plated on
poly-L-ornithine coated coverslips. For calcium imaging, cells were loaded with Fura-2 dye for
40 minutes and then imaged. Solutions were applied with a gravity driven perfusion system. The
0 Ca2+ solution contained 0.2 mM EGTA to chelate all residual Ca2+ in the buffer. This Ca2+ free
solution was allowed to wash over the cells for a few minutes before application of 1 µM CCh.
Controls were cells transfected with only EGFP. Data are means ± SEM for 19 cells for each
condition.
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6.2 Ca2+, H+ and PLC
I tested whether the constitutively active PLCδ1 could overcome the necessity for Ca2+ to
achieve maximal activation or the necessity for intracellular acidification to achieve the rapid
kinetics of channel activation. Overexpression of constitutively active PLCδ1 was unable to
support TRPC4 activation in the presence of 10 mM BAPTA (Fig 47a), suggesting that for its
action on TRPC4, [Ca2+]i rises are still needed.
Also the kinetics of channel activation at alkaline intracellular pH (8.5) was slower than
that at pH 7.2 (Fig 47b) suggesting that protonation of intracellular targets still facilitated TRPC4
activation despite the constitutive activation of PLCδ1. It should be noted that the increased
kinetics seen with overexpression of PLCδ1 or inhibition of RhoA are still slower than the fast
kinetics seen with coincident Gi/o and Gq stimulation or coincident intracellular acidification and
[Ca2+]i rise. Therefore, although PLCδ1 activation is a necessary part of the Ca2+ dependent
facilitation of TRPC4 activation, it might not fulfill the same role as intracellular acidification.
Clearly, the Ca2+ dependent facilitation mechanism and the proton dependent facilitation
mechanism are distinct, although they are not mutually exclusive in the physiological scenario
since the proton dependent facilitation also has a [Ca2+]i dependence.
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Figure 47. PLCδ1-ΔXY does not reverse Ca2+ and H+ dependence
a, Whole-cell currents evoked by simultaneous application of DAMGO (1 µM) and IM (1 µM)
in cells that stably co-expressed TRPC4β and µOR and transiently transfected with cDNAs for
RhoAL63 (to inactivate endogenous PLCδ1) and PLCδ1-XY. Cells were tested in two conditions,
one with 10 mM BAPTA in the patch pipette and the second with 0.05 mM EGTA and no added
Ca2+. b, The same set of cells as in a. were tested under two different conditions, one with pHi
clamped inside the cell at 7.2 and the other at 8.5 using 50 mM HEPES. Summary data (means ±
SEM) for DAMGO + IM evoked peak currents at -60 mV are shown. * p < 0.05 vs control (pHi
7.2) by unpaired t test.
Ca2+ and H+ act cooperatively from the cytoplasmic side to facilitate Gi/o-mediated TRPC4
activation. The protonation reactions caused by the acidic pHi are therefore merely facilitatory
and not necessary for channel activation as tested within the experimental bounds described in
Ch 5. Within the range of pH modulations performed here, inhibition of local pH fluctuations by
using high concentrations of HEPES prevented the facilitation. Interestingly, both Ca2+ and H+
only work within rather narrow concentration ranges, revealing an extremely tight regulation by
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these factors on TRPC4 function. The micromolar [Ca2+]i dependence and its bidirectional effect
suggest a highly dynamic nature of cytosolic Ca2+ on TRPC4 activation, consistent with the
observed high sensitivity to the slow Ca2+ chelator, EGTA. Even with as low as 0.5 mM
intracellular EGTA, µOR-mediated TRPC4 activation was inhibited, implicating that Ca2+ has to
travel a small distance from its source of generation to the target(s). The primary source of Ca2+
in PLC signaling is ER Ca2+ release mediated by IP3Rs. This activity also causes store-operated
Ca2+ influx. Either of these may provide the initial Ca2+ trigger for TRPC4 activation, but the
more robust TRPC4 currents may arise from the positive-feedback mechanism owing to the Ca2+
permeability of opened TRPC4 channels that result in a cascade of activation of neighboring
(TRPC4) channels. Thus, the initial cause of [Ca2+]i rise may be immaterial for the facilitation. In
neurons, native TRPC4 activity is strongly facilitated by the opening of voltage-gated Ca2+
channels (Tian, Thakur et al. 2013) but in HEK293 cells, IP3R-mediated ER Ca2+ release seems
to be critical even though it can be substituted by other mechanisms, e.g. IM-mediated [Ca2+]i rise
or clamping the [Ca2+]i to micromolar levels.
The separation of Ca2+ and proton dependent processes is complicated by the fact that Ca2+
chelating agents and sensors are also pH dependent. However, there are some clues from the
elucidation of the proton dependence of Drosophila TRP channels which could be put to use in
this case. The protonation dependent redox reaction associated with INAD PDZ domains (Liu,
Wen et al. 2011) could serve as s a template to examine a similar modulation of cysteine residues
in the intracellular domains of TRPC4 and its associated proteins.
The effect of protons on TRPC4 may be indirect. Although intracellular acidification
facilitated TRPC4 activation, this observation was made by manipulating the pHi globally (across
the entire cytosol). In the whole-cell configuration, a majority of cellular factors may be affected.
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In the outside-out patch configuration, although the pH in proximity to the channel is better
controlled than in whole-cells – several intracellular components may get extracted along with
the patch and regulated by pH. Therefore, the effect of protons on TRPC4 may still be indirect.
As such, the matching of the fast kinetics (in whole-cell patch clamp) seen in the two conditions:
1) with coincidental Gi/o + Gq activation and 2) with coincidental Gi/o activation, [Ca2+]i and [H+]i
rise – may be a correlation. Although the Gq dependent facilitation of TRPC4 was slowed by
clamping the intracellular pH to an alkaline value (8.5) - suggesting that the H+ dependent
facilitation may indeed be downstream of Gq in HEK293 cells, the manipulation of intracellular
pH to 8.5 was also global - making the effect on TRPC4 currents probably a result of non-specific
actions.
To examine whether protons directly modulate TRPC4, two types of experiments could
be performed: a reconstitution of purified TRPC4 subunits in artificial lipid bilayers, or the testing
of TRPC4 mutants in which appropriate protonatable residues are substituted with nonprotonatable ones. There are several conserved amino acid residues in the cytoplasmic as well as
pore regions of TRPC4 and TRPC5 that are candidates for pH regulation in the range optimal for
TRPC4 and TRPC5 activation. The most likely candidate is histidine (H) which has a side chain
pKa of 6.04 and is conserved frequently between TRPC4 and TRPC5 in the N termini, the interhelical cytoplasmic domains, the pore loops and the C termini (Fig. 48). The next closest
candidate is glutamic acid (E) with a side chain pKa of 4.25. It has been shown previously that
extracellular glutamate residues at position 543 in TRPC5 are responsible for the sensitivity to the
cations Gd3+, La3+ and extracellular acidification. Although the pKa of glutamate side chain in the
free amino acid is rather low, the pKa values of solvated glutamates within the TRPC4 structure
are unknown. It is possible that the pKa values of the residues in the solvated structure fall within
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the range tested in Chapter 3 and that E542, E543 or other residues may underlie the pHi
dependent regulation of TRPC4.
N terminus

. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
P L R I V RA ES EL S P S EKA Y L N AV EK GDY AS V KK S L E EA E I Y F K I N I NC I DP L GRT A L L
P L R I V RA ES EL S P S EKA Y L N AV EK GDY AS V KK S L E EA E I Y F K I N I NC I DP L GRT A L L
P L Q I V RA ET EL S A E EKA F L S AV EK GDY AT V KQ AL Q EA E I Y Y NV N I NCM DP L GRS A L L

TRPC4α MAQ F Y Y K RNV NAP Y RD R I
TRPC4β MAQ F Y Y K RNV NAP Y RD R I
TRPC5 MAQ L Y Y K KV N Y S P Y RD R I

. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . .
L HA I RK EV V GAV EL L L NHK KP S G EKQ V P P I L L DKQ F S E F T P D I T P I I L AA HT NN Y E I
L HA I RK EV V GAV EL L L NHK KP S G EKQ V P P I L L DKQ F S E F T P D I T P I I L AA HT NN Y E I
L Y A I RK EV V GAV EL L L S Y R KP S G EKQ V P T L MMDT Q F S E F T P D I T P I ML AA HT NN Y E I

. . . . | . . .
KAL AS P S L
KAL AS P S L
KAL AS P S L

. . .
I AI
I AI
I AI

. | . . . . | . . . . | . . . . | . . . . |
EN ENL EL I EL L L S F NV Y V GDAL
EN ENL EL I EL L L S F NV Y V GDAL
EN ENL E I M EL L L NH S V Y V GDAL

. . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
I KL L VQ KGV S V P R P H EV RCN CV ECV S S S DV DS L RH S RS R L N I Y
I KL L VQ KGV S V P R P H EV RCN CV ECV S S S DV DS L RH S RS R L N I Y
I KL L VQ KRV T I P R P HQ I RCN CV ECV S S S EV DS L RH S RS R L N I Y

. | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . .
I A L S S EDP F L T A FQ L SWEL Q EL S KV EN E F K S EY E EL S RQ CKQ F AKD L L DQ T RS S R EL E I
I A L S S EDP F L T A FQ L SWEL Q EL S KV EN E F K S EY E EL S RQ CKQ F AKD L L DQ T RS S R EL E I
I A L S S EDP I L T A F RL GWEL K EL S KV EN E F K A EY E EL SQQ CKL F AKD L L DQ ARS S R EL E I

. . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
I L N Y RD DNS L - I E EQ S GN DL AR L KL A I KY RQ K E
I L N Y RD DNS L - I E EQ S GN DL AR L KL A I KY RQ K E
I L N HRD DHS E EL D PQ KY H DL AK L KV A I KY HQ K E

. | . . domain
. . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . .Cytoplasmic
.
|
SQ H I D RS D L NRQGP P P T I V EWM I L PWV L G F I WG E I KQMWDGGL Q DY I HDWWN
F V AQ P NCQQ L L AS RWY D E F P GWR RRHWAV
SQ H I D RS D L NRQGP P P T I V EWM I L PWV L G F I WG E I KQMWDGGL Q DY I HDWWN
F V AQ P NCQQ L L AS RWY D E F P GWR RRHWAV
K EMWDGG F T EY I HDWWNL
F V AQ P NCQQ L L AT LWY DG F P GWR RKHWV V K

Cytoplasmic domain
. | . . .
L RL
L RL
RL

. | . . . . | . . . . | . . . . | . . .
I S L F T AN S H L GP L Q I S L GR
I S L F T AN S H L GP L Q I S L GR
I S L F T AN S H L GP L Q I S L GR

Pore loop

**

. . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
N GL NQ L Y F Y Y E ET - - - KGL S CK G I R C EKQNN A F S T L F ET L Q S L FWS I F GL I N L Y V T N V KAQ H E F T E F V
N GL NQ L Y F Y Y E ET - - - KGL S CK G I R C EKQNN A F S T L F ET L Q S L FWS I F GL I N L Y V T N V KAQ H E F T E F V
GL NQ L Y F Y Y ET RA I D EP NNCK G I R C EKQNN A F S T L F ET L Q S L FWS V F GL L N L Y V T N V KA RH E F T E F V GA T

C terminus
| . . . . | . . . . |
L I AMMNNS YQ L
L I AMMNNS YQ L
NNS YQ L

. . . . | . .
I ADHA D I
I ADHA D I
I ADHA D I

. . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . .
EWK F A RT KLWMS Y F E EGGT L P T P F NV I P S P KS L WY L V KW I WT H L CKKKM - - - RRK P ES F GT I G RR AAD NL RR HHQYQ EVMR
EWK F A RT KLWMS Y F E EGGT L P T P F NV I P S P KS L WY L V KW I WT H L CKKKM - - - RRK P ES F GT I G RR AAD NL RR HHQYQ EVMR
EWK F A RT KLWMS Y F D EGGT L P P P F N I I P S P KS F L Y L GNWF NN T F CP KR DP DGRRR RHNL RS F T ER HAD S L I Q NQ HYQ EV I R

. | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . .
NL V KRY V AAM I R EAKT E EGL T E ENV K EL KQ D I S S F R F EV L GL L RGS KL S T
NL V KRY V AAM I R EAKT E EGL T E ENV K EL KQ D I S S F R F EV L GL L RGS KL S T
NL V KRY V AAM I RN S KT N EGL T E EN F K EL KQ D I S S F RY EV L D L L GN RKH P -

. | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . .
I QS ANAA S S A DS D EKSQ S EGNGK DKR KNL S L F DL T T L I H P RS AA I A S ER
I QS ANAA S S A DS D EKSQ S E - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - RR S L S T S S A D F SQ RDD T NDGS GGAR AKS K S V S F N V GCK KKA CHGA P L I

. . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . .
HN L S NGS AL V VQ EP P R EKQ RK V N F V AD I KN F GL F HRR S KQ NA A EQN ANQ I F S V S E E I T RQQ AAGA L ER N I EL ES KGL AS RGDR S I P GL N EQ C V L V DHR ERN
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - E E I T RQQ AAGA L ER N I EL ES KGL AS RGDR S I P GL N EQ C V L V DHR ERN
RT V P RA S GAQGKP K S ES S S KR S FMGP S F KK L GL F F S K F NGQT S EP T S EPMY T I S DG I AQQH CMWQ D I R Y SQME - KGK A EAC SQ SQMNL G EV EL - - - G E I RG

. | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | .
T DT L GL QV GKRV CS T F KS EKV V V EDT V P I I P K EK HAH E EDS S I DY D L S P T DT A AH ED Y V T T R L
T DT L GL QV GKRV CS T F KS EKV V V EDT V P I I P K EK HAH E EDS S I DY D L S P T DT A AH ED Y V T T R L
AAA RS S ECP L AC S S S L HCA S G I CS S NS KL L D S S EDV F ETWG EACDL L MHKWGD GQ E EQ V T T R L

Figure 48. Candidate protonatable residues in cytoplasmic and pore loop domains of
TRPC4 and C5
Sequence alignment of mouse TRPC4α, TRPC4β and TRPC5, A performed using Multalin
(multalin.toulouse.inra.fr/multalin/) and exported via Bioedit (mbio.ncsu.edu) to MS Powerpoint
for editing. Only regions exposed to the cytoplasm are shown. Transmembrane regions and
extracellular loops between transmembrane-helices have been omitted (indicated by grey bars).
Histidine (H) residues are in red and glutamate (E) residues are in blue. E542 and E543 that were
previously mutated in TRPC4β (Ch. 5) are indicated by asterisks.
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Any reconstitution experiment would have to account for the fact that TRPC4 activation
requires Gi/o (possibly through direct interactions), elevated [Ca2+]i and PLCδ1. Therefore, in
order to test the effects of pH on TRPC4 activity, purified G protein subunits, 10 µM or so free
Ca2+ and either purified PLCδ1 would have to be added at the intracellular side or a membrane
bound myristolyated PLCδ1 mutant could be used.
It is likely that the effects of Ca2+ and H+ converge on CaM. It is known that proton
exchange occurs when CaM associates with Ca2+ (Sellers, Laynez et al. 1991). The protons
released by CaM upon Ca2+ binding may account for a part of the H+ dependent facilitation of the
TRPC4 current. The facilitatory effect of low pH may also be through a H+ dependent facilitation
of CaM. It has been reported that low pH can substitute the need for high [Ca2+] to associate with
CaM and cause it to change its configuration from a collapsed state to an extended shape (Pandey,
Dhoke et al. 2014). Therefore although a biphasic nature of pH regulation of CaM or Ca2+-CaM
has not been described in the pH range tested here, it is possible that protonation of CaM residues
might modulate its activity in either or both of the two phases seen in Chapter 3 (Fig. 39c).
Additionally the point of convergence of Ca2+ and H+ may also be at PLCδ1 which has a pH
sensitivity that is biphasic (Ryu, Suh et al. 1987, Homma, Imaki et al. 1988). The peak activity
(in purified proteins) is seen between pH 5.0 and 7.0, with strong inhibition seen at both acidic
and alkaline pH values that are beyond this range.
In summary, the optimal [Ca2+] and pHi ranges observed for TRPC4 activation coincide
with optimal [Ca2+] and pH ranges for CaM and PLCδ1. As a result of this coincidence, the
maximal TRPC4 activity may be an emergent property from the maximal activation of both CaM
and PLCδ1.
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6.4 The role of RhoA
In my study, RhoA was largely used as an experimental tool to inhibit PLCδ1, following
previous work which had shown RhoA dependent inhibition of an SKF-96365 -sensitive Ca2+
entry pathway downstream of Gi/o and PLCδ1 signaling (SKF-96365 is a broad spectrum inhibitor
of store operated channels) (Murthy, Zhou et al. 2004). However, this raises interesting
possibilities for the regulation of PLCδ1 via the G12/13-Rho-GEF-RhoA pathway. p115-RhoGEF,
PDZ-RhoGEF and LARG (leukemia-associated rhoGEF) are endogenously expressed in HEK293
cells (Wang, Liu et al. 2004). Both G12 and G13 show high mRNA levels as well in HEK293 cells
(Atwood, Lopez et al. 2011). In addition to G12/13, both receptor activation of Gq and
overexpression of the constitutively active mutant GqQL can activate RhoA independent of a G13RhoA pathway (Chikumi, Vázquez-Prado et al. 2002). Indeed, this may constitute another
mechanism, in addition to PIP2 depletion, that underlies the strong inhibition of TRPC4 by
overexpression of GqQL (Fig. 46). The activation of Gq/12/13 proteins would, in theory, inhibit
PLCδ1 and TRPC4 rather than facilitate the activation of both proteins as shown here. Why this
does not occur in the assays described above is intriguing. Interestingly, the GqQL dependent
inhibition of TRPC4 was reversed by the constitutively active PLCδ1-ΔXY mutant (Fig. 46).
Whether the PLCδ1-ΔXY mutant escapes a RhoA dependent inhibition is not known, but this
might be testable by co-immunoprecipitation assays. Additionally, ARHGAP6 – a RhoA
activating protein, known to inhibit PLCδ1 (Ochocka, Grden et al. 2008) would be expected to
inhibit TRPC4.
6.4 The roles of G protein subunits
Inhibiting PLC using U73122 and RhoA revealed that there is a PLC component,
downstream of or in parallel with the Gi/o pathway that is needed for TRPC4 activation. Though
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PLCβ1/3 are known to be stimulated weakly by Gβγ subunits, it is unlikely that Gi/o proteins
induce TRPC4 activation via Gβγ-mediated stimulation of PLCβ (PLCβ2 is not expressed in
HEK293 cells). In HEK293 cells, µOR stimulated Gi/o activation rarely elicited [Ca2+]i rise,
indicating a poor production of IP3. In addition, if PLCβ was the sole reason for Gi/o-coupled
receptors to trigger TRPC4 activation, then Gq/11-coupled receptors would be more effective at
opening TRPC4 channels than the Gi/o-coupled ones. Additionally, the overexpression of
exogenous PLCβ2 which is strongly activated by Gβγ, did not result in larger peak currents or
faster kinetics. Neither did it overcome a RhoA nor a GqQL induced inhibition. Therefore, a Gβγ–
PLCβ pathway is unlikely to underlie the activation mechanism of TRPC4 channels. The strong
synergy between Gq/11 and Gi/o stimulation for TRPC4 activation would also be difficult to explain
without assigning a distinguished role to Gi/o. The previous study demonstrating the specific
involvement of Gi/oα, especially Gi2α, rather than Gβγ, in TRPC4 activation (Jeon, Hong et al.,
2012) also excludes Gβγ-PLCβ coupling as the mechanism of Gi/o action. However, in previous
microtiter plate-based fluorescence membrane potential assays (performed by Dr. M.X. Zhu, not
shown) and in patch clamp assays shown below (Fig. 49a), the suppression of Gβγ activity by
overexpression of the C-terminus of β adrenergic receptor kinase (βARK-Ct) did inhibit TRPC4
activation, suggesting that Gβγ is involved in the mechanism in some manner. Since the lack of
functional Gβγ also prevents G protein cycles and hence the GTP/GDP exchanges of Gi/oα, these
Gβγ-sequestering experiments do not necessarily suggest a specific involvement of either Gi/oα or
Gβγ. Furthermore, in GST pulldown assays purified Gβ1γ2 subunits showed association with both
full length TRPC4α C-terminus (615 – 974) and with the TRPC4α-765-974 fragment (Fig. 49b).
Previously, the CIRB site had been identified as the site of interaction with Gi2α (Jeon, Hong et
al. 2012). The presence of a Gβ1γ2 binding site downstream of the Gi2α binding site suggests a
120

novel role for Gβ1γ2 subunits to directly interact with the channel. Whether the direct interaction
is necessary for TRPC4 function is not known.
Yet, PLC activity is required for Gi/o-mediated TRPC4 activation as shown by the
inhibitory effect of U73122 and the increased probability and rate of TRPC4 activation with the
costimulation of Gq/11-PLCβ and EGFR-PLCγ. The sensitivity to U73122, Ca2+, RhoA and the
dnPLCδ1 mutant suggests that PLCδ1 is a necessary component in the Gi/o -TRPC4 pathway.
Whether there is cross-talk between PLCδ1 and Gi/o is not known. It is likely that PLCδ1 and Gi/o
are independently activated, but simultaneously necessary for TRPC4 activation. The PLCδ1, Gi/o
-TRPC4 mechanism may explain both phases in the biphasic activation of a whole cell TRPC4
current. In the initial phase, with small currents, it is possible that an activation of a small set of
TRPC4 channels on the plasma membrane directly by Gi/o and a few molecules of PLCδ1 in the
vicinity, locally activated for whatever reason, can slowly elevate [Ca2+]i sufficiently to levels
which are needed to activate PLCδ1 (1 – 10 µM, Allen 1997) in the entire cell, which subsequently
leads to the optimum conditions for activating a maximal number of TRPC4 channels in the cell.
The global activation of PLCδ1 may underlie the fast rising phase, at the peak of which, the
maximal whole-cell TRPC4 currents are achieved. The fact that Gq/11 activation or [Ca2+]i
elevation by other means categorically does not allow for TRPC4 activation in this manner
reinforces the necessity for Gi/o stimulation and points towards a way in which PLCδ1 may play
a very specific role in TRPC4 activation either through specific localization or through a
downstream component that is absent in Gq/11-PLCβ. Therefore, both a direct action of Gi/o
subunits with TRPC4 and activation of the PLC pathway can be critical for TRPC4 activation.
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Figure 49. The role of Gβγ in TRPC4 activation
a. Similar to figure 8, in HEK 293 cells stably expressing µOR and TRPC4β, M3R and βARKCt were cotransfected. Cells were patched in the whole-cell configuration. Whereas
overexpression of M3R led to robust activation of TRPC4 currents in response to CCh (100 µM),
similar to that shown in figure 8, coexpression of βARK-Ct suppressed the current strongly.
Summary data (means ± SEM) for CCh-evoked peak currents at -60 mV are shown. * p < 0.05 vs
control by unpaired t test. b. Purified Gβ1γ2 subunits and GST (kindly provided by Dr. C.
Dessauer, UT) were tested along with GST fused TRPC4α C-terminus fragments. Gβ1γ2 subunits
showed association with full length C terminus of TRPC4α (615 – 974) and with the TRPC4α765-974 fragment, suggesting that Gβ1γ2 interacts in a region downstream of the CIRB domain
identified to be the site of Gi2α interaction (Jeon, Hong et al. 2012).

6.5 The role of scaffolding proteins
The proton dependent regulation of the Drosophila TRP is regulated by the scaffolding
protein INAD consisting of 5 PDZ domains. The scaffolding protein endogenous to HEK293 cells
that is known to be associated with TRPC4 is NHERF which consists of two PDZ domains.
Moreover, NHERF has been shown to underlie the biphasic activation kinetics of TRPC5, where
deletion of the PDZ binding domain at the C terminus of TRPC5 eliminated the biphasic mode of
activation (Obukhov and Nowycky 2004). If the proton regulation of TRPC4 is similar to that of
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the Drosophila TRP, I hypothesized that disruption of TRPC4-NHERF association would alter
the kinetics of TRPC4 activation as well and such a change in the association may underlie the
mechanism of proton dependent facilitation.
However, a TRPC4β mutant with the PDZ binding site deleted had similar kinetics of
current development as the wild type channel. Stimulation by DAMGO or DAMGO + IM or
stimulation by DAMGO following a pre-application of IM still resulted in biphasic kinetics of
current development (Fig. 50). These preliminary results have two implications: 1) TRPC4
activation mechanism by Gi/o differs from the Gq/11-dependent TRPC5 activation mechanism
described previously and 2) the critical site of proton facilitation for TRPC4 is not at the Cterminal end where the channel associates with a PDZ domain-containing scaffolding protein.
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a

1 µM DAMGO

b

1 µM IM+1 µM DAMGO

c

1 µM IM

1 µM DAMGO

1.5 nA
10 s

Figure 50. The C-terminal PDZ-binding domain does not regulate TRPC4 activation
kinetics
A TRPC4β mutant with the PDZ-binding domain at the C-terminal end deleted was subcloned, in
pIRESneo vector and transiently transfected into HEK293 cells stably expressing µOR. Cells
were studies by whole-cell recording after 16-24 hours as shown in Fig. 23, with DAMGO and
IM applied as indicated. Concentration of EGTA in all patch pipette solutions was 0.05 mM with
no added Ca2+.

6.6 Remaining questions and suggested future experiments
In summary, though I have made advances in identifying the elements underlying the
[Ca2+]i dependent facilitation of TRPC4 activation, several old and new questions need to be
addressed. First, what is the mechanism of Gi/o’s action on TRPC4? If indeed the action of Gαi/o
subunits is by covalent interactions with the TRPC4 CIRB domain, would, for example, the
interchange of TRPC4 and TRPC6 CIRB domains render TRPC4 insensitive and TRPC6 sensitive
to Gi/o stimulation?
Second, what is the role of Gβγ subunits? Do they behave interchangeably with Gαi/o
subunits or serve as scaffolding proteins supplementing Gαi/o in direct interaction with the TRPC4
CIRB domain? This could be tested by running competitive binding assays between Gαi/o, Gβγ
and GST-tagged-TRPC4 CIRB domain fragments.
Also, it has not been determined whether or not Gαi/o or Gβγ facilitates the activation of
PLCδ1 directly or indirectly. Previous in vitro assays that examined the interactions of Gβγ
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subunits with purified PLCδ1 showed a 2 fold facilitation of PLCδ1 activity by Gβ1γ2 subunits
(Park, Jhon et al. 1993). These assays were performed in the presence of 200 nM free Ca2+. It is
likely that PLCδ1 might need a higher concentration of Ca2+ as a cofactor in its interactions with
Gβγ. These assays could be reproduced with different buffer conditions to address this question.
It is possible that this Gβγ dependent PLCδ1 activity also underlies the inhibition seen in Fig. 46.
Other G proteins such as Gαh (transglutaminase II) which increases the affinity of PLCδ1
to Ca2+ (Feng, Rhee et al. 1996) would be expected to facilitate TRPC4. It would be interesting
to see whether overexpression of Gαh would lead to such facilitation.
Third, are the mechanisms of CaM dependent facilitation and PLCδ1 dependent
facilitation independent? Would the IRB mutant, which showed a facilitation during sub-maximal
activation, be as strongly inhibited as the wild-type channel is - in the presence of dn-PLCδ1?
What is the nature of PIP2’s interaction with TRPC4? The data above suggests that PIP2
might behave only as a chaperone for PLCδ1. In this case, would a modified membrane localized
PLCδ1 mutant be able to reverse the GqQL dependent inhibition in a manner similar to PLCδ1ΔXY?
Finally, what is the nature of PLCδ1’s interaction with TRPC4? Is it a covalent interaction
with TRPC4, or is it the creation of a PIP2 hydrolysis product in close proximity to the channel
that is critical for TRPC4 gating?
Addressing these questions would help to more completely elucidate the signal integration
pathway associated with TRPC4 and identify its physiological significance.
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